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ABSTRACT
An urgent demand for the development of new antibiotics has been created by the
increase in clinical cases involving drug-resistant pathogenic bacteria. A novel target for
antibacterial development is acetyl-CoA carboxylase, a multifunctional enzyme that
catalyzes the first committed step in fatty acid synthesis. The bacterial form of the enzyme
consists of three proteins: biotin carboxylase, biotin carboxyl carrier protein, and
carboxyltransferase. The research presented in this dissertation describes dual-ligand
inhibitors

incorporating

selective

inhibitors

against

biotin

carboxylase

and

carboxyltransferase that were synthesized by covalently attaching them with saturated
hydrocarbon linkers containing 7 and 15 carbon atoms. The ability to inhibit two different
enzymes with the same compound expounds on the theory of increasing overall potency
and impeding the ability for the development of resistance.
Kinetic results revealed both dual-ligands displayed inhibition constants in the
nanomolar range. However, microbiology assays showed the dual-ligand with the longer
linker did not exhibit antibacterial activity. The dual-ligand with the shorter linker showed
antibacterial activity against both Gram-positive and Gram-negative organisms as well as
decreased susceptibility to the development of bacterial resistance. These results suggest
that the length and chemical properties of the covalent linker is critically important for
maintaining the antibacterial activities of the two incorporated pharmacophores. Based on
biochemical activities, likely reflects alteration in cell permeability or avoidance of
intrinsic efflux of the tested dual-ligand molecules.

x

The natural product moiramide B is a broad spectrum antibiotic that inhibits the
carboxyltransferase component of acetyl-CoA carboxylase.

A crystal structure of

moiramide B was solved in complex with carboxyltransferase. The structure shows that
only the (S)-methyl pyrrolidinedione head group of moiramide B is used to inhibit the
enzyme by taking advantage of the two oxyanion holes that the enzyme normally uses to
stabilize enolate anions that form in the substrates during catalysis. The fatty acid tail of
moiramide B appears to be only needed for entry into the bacterial cell. Structure-activity
relationship studies validated the necessary structural features that contribute to the
inhibitory and antibacterial properties of moiramide B. These findings can lead to further
design and development of a potent carboxyltransferase antibacterial agent.

xi

CHAPTER 1: INTRODUCTION
1.1

ANTIBIOTICS
Antibiotics can be divided into two methods of action: inhibition of microorganism

replication (bacteriostatic) or cytotoxic (bactericidal), Figure 1.1.1-2 The term ‘antibiotic’
was first defined by Selman Waksman in 1942 as "inhibiting the growth or the metabolic
activities of bacteria and other microorganisms by a chemical substance of microbial
origin.”3 Typical antibiotics are either natural products, semisynthetic derivatives of

Log Number of Viable Bacteria

natural products, or completely synthetic in origin.1
Addition
of drug

Control

Bacteriostatic Agent

Bactericidal Agent
Time

Figure 1.1. The biological effects of bacteriostatic versus bactericidal antibiotics on
growing cells; adapted from Walsh (2003).1
1.1.1 History of Antibiotics
The idea for creating drugs that would selectively target and kill bacteria was
introduced by Paul Ehrlich who developed the concept of synthetic antibiotic
chemotherapy.4 The first reported antibiotic used to treat an infectious disease was in 1910
when Ehrlich discovered Salvarsan, an arsenic-based compound used to cure syphilis.5
This paved the way for the identification of sulfonamides, or sulfa drugs, in the 1930s
which were designated as the first class of antibiotics that were produced solely by
1

chemical synthesis.6 The first commercially available sulfa drug, Prontosil, was developed
by Gerhard Domagk and coworkers at Bayer in 1932.4 The most notable antibacterial
agent was discovered by Sir Alexander Fleming in 1929 when he isolated penicillin from
Penicillium rubens and found it displayed antibiotic properties.7 Penicillin is classified as
a -lactam antibiotic and with the help of Ernest Chain and Howard Florey, penicillin G
was introduced clinically in 1942.6, 8
After the introduction of -lactams, there was a dramatic increase in the number of
antibiotic classes being discovered and introduced to the market from the 1940s to the
1960s.

These new classes included: polyketides, aminoglycosides, macrolides,

glycopeptides, and quinolones. Since the introduction of quinolones in 1962, no novel
antibiotic classes were identified until linezolid was introduced to the market in 2000,
Figure 1.2.9 The most recently discovered class is lipopeptides, which includes the
antibiotic daptomycin. Daptomycin was introduced in 2003 as a treatment for drugresistant Gram-positive pathogens.10

Figure 1.2. Timeline showing introduction of new classes of antibiotics into clinical
practice; from Walsh (2003).11
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1.1.2 Modes of Action
The classes of antibiotics are grouped together based on their targets in the bacterial
cell. The four major targets are: cell wall synthesis, protein synthesis, DNA or RNA
synthesis, and folate coenzyme synthesis, Figure 1.3.1, 12
Class
Target
Bacterial Activity
Sulfa drugs
Folate Coenzyme Synthesis
Gram-positive
-Lactams
Cell Wall Biosynthesis
Broad-spectrum
Aminoglycosides
Protein Biosynthesis
Broad-spectrum
Phenylpropanoids
Protein Biosynthesis
Broad-spectrum
Macrolides
Protein Biosynthesis
Broad-spectrum
Polyketides
Protein Biosynthesis
Broad-spectrum
Rifamycin
RNA Synthesis
Broad-spectrum
Glycopeptides
Cell Wall Biosynthesis
Gram-positive
Quinolones
DNA Synthesis
Broad-spectrum
Lantibiotics
Cell Wall Biosynthesis
Gram-positive
Streptogramins
Protein Biosynthesis
Gram-positive
Oxazolidinones
Protein Biosynthesis
Gram-positive
Lipopeptides
Bacterial Membrane
Gram-positive

Notable Examples
Prontosil
Penicillin, Ampicillin
Streptomycin, Kanamycin
Chloramphenicol
Erythromycin
Tetracycline, Oxytetracycline
Rifampin
Vancomycin
Ciprofloxacin, Fluoroquinolones
Nisin
Pristinamycin
Linezolid
Daptomycin

Figure 1.3. List of drug classes, their targets, bacterial activity, and notable examples in
order by date of introduction to the market; adapted from Lewis (2013).12
The antibiotic classes that target cell wall biosynthesis include the -lactams and
glycopeptides. The composition of the cell wall of both Gram-negative and Gram-positive
bacteria contains a peptidoglycan (PG) layer, though the PG layer is considerably thicker
in Gram-positive bacteria. Antibiotics containing a β-lactam (Figure 1.4) bind irreversibly
to penicillin-binding proteins (PBPs), which are involved in transpeptidase activity to
cross-link peptidoglycan units. This binding results in cell wall instability and increases
permeability.1-2, 13 Glycopeptides, such as vancomycin, bind to the amino acid precursors
used to assemble the cell wall, which prevents the bound amino acids from binding to the
PBPs. Glycopeptides are only potent against Gram-positive bacteria due to their inability
to penetrate the Gram-negative outer membrane.1, 14
3

Figure 1.4. The core structure of penicillin with variation occurring at the R group. The
-lactam ring is in red.
The antibiotic classes that inhibit protein biosynthesis, bind to the 50S subunit or
30S subunit of the bacterial ribosome and include: aminoglycosides, macrolides,
polyketides, and oxazolidinones, to name a few.12 Erythromycin, a macrolide, binds to the
50S ribosomal subunit and prevents aminoacyl-tRNA translocation from the A site to the
P site. This action causes a premature release of peptidyl-tRNA intermediates that are
required for polypeptide elongation.1, 15 A second group of antibiotics that bind to the 50S
subunit are the oxazolidinones, which inhibit the formation of the ribosome complex
needed for the initiation of protein synthesis.16

The broad-spectrum tetracycline (a

polyketide antibiotic) inhibits protein synthesis by blocking the attachment of aminoacyltRNA from binding to the A site of the 30S subunit of the ribosome, preventing the
incorporation of new amino acids to the polypeptide chain.17
The antibiotic classes that target DNA or RNA synthesis include the quinolones
and rifamycin.

The quinolones inhibit DNA synthesis by interacting with either

topoisomerase IV or DNA gyrase (topoisomerase II). These topoisomerases are critical in
maintaining the conformations required for DNA replication.18 The quinolones inhibit the
topoisomerase reactions resulting in the RNA polymerase and helicase being blocked at
the replication fork leading to cell death.19 The antibiotic rifampin is used to inhibit RNA
synthesis by binding in an allosteric site and sterically blocking the elongation of RNA.20
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Sulfa drugs are synthetic compounds responsible for inhibiting folate coenzyme
synthesis and are considered bacteriostatic. The most recent generation of the sulfa drug,
sulfamethoxazole, inhibits dihydropteroate synthase and is used in combination with
trimethoprim, which inhibits dihydrofolate reductase.

By using these two drugs in

combination, folic acid metabolism is halted. Inhibition of the folate coenzyme synthesis
pathway ultimately leads to the lack of production of thymine, which is an essential
nucleotide for DNA biosynthesis.1, 21
1.1.3 Resistance Mechanisms
Over the years, pathogenic bacteria have formed resistance mechanisms to current
treatments due to the large number of bacterial cells in populations and their short
generation times. While this resistance develops naturally over time, the inappropriate use
and distribution of antibiotics in a clinical setting plays a fundamental role in the formation
of resistant bacteria.22-23 Bacteria utilize a variety of mechanisms to ensure their survival
that include active efflux, inactivation, or modification of the antibiotic, Figure 1.5.1-2

Figure 1.5. Antibiotic-resistant bacteria owe their drug insensitivity to resistance genes.
These genes might code for a variety of mechanisms: (A) efflux pumps that eject antibiotics
from cells, (B) genes that give rise to enzymes that degrade the antibiotics, or (C) genes
that chemically alter the antibiotic; from Levy (1998).2
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Efflux pump systems play an integral role in the multidrug resistance of clinically
important Gram-negative pathogens and have been identified and characterized in strains
of Escherichia coli and Pseudomonas aeruginosa.24-28 Efflux pumps are transmembrane
systems that transport substances from within the cell into the external environment and
can be specific for one substrate or a range of compounds. These systems are energy
dependent and consist of three components: a resistance nodulation division (RND)
exporter protein found in the cytoplasmic membrane, a gated outer membrane protein, and
a membrane fusion protein (MFP) that links the two membrane proteins, Figure 1.6.27

Figure 1.6. Proposed structure and function of the MexAB-OprM and related efflux pumps
of P. aeruginosa. Antibiotics can be captured from the periplasmic space, cytoplasmic
membrane, and/or cytoplasmic space by MexB, D, F, or Y (RND exporter proteins).
MexA, C, E, or X (MFP proteins) serve as conduits between the cytoplasmic and outer
membranes. OprM, J, or N (gated outer membrane porin proteins) serve as the final step
in removal of the antibiotic from the cell; from Aeschlimann (2003).27
Different combinations of proteins create efflux pump systems that allow for
selectivity of specific antibiotics. The MexA-MexB-OprM pump in P. aeruginosa has the
broadest-spectrum of activity by recognizing and ejecting tetracycline, quinolones, and
most -lactams.1 Genetic deletion of this pump results in a significant decrease in the
6

minimum inhibitory concentration (MIC) values for many antipseudomonal drugs.27 The
MexX-MexY-OprM pump system is also involved in multidrug resistance, though it has a
narrower spectrum of selectivity than MexA-MexB-OprM. The MexX-MexY-OprM
pump system removes aminoglycosides, fluoroquinolones, marcolides, and tetracycline.27
The most common pump system in E. coli is the AcrA-AcrB-TolC efflux pump, with TolC
being the outer membrane protein. Deletion of the acrAB genes results in hypersensitivity
of E. coli to various antibacterial agents.29 The Acr efflux system selectively expels
chloramphenicol, fluoroquinolones, rifampin, tetracycline, and some -lactams.30
Another common resistance mechanism is the inactivation of the antibiotic. This
method is more often observed with natural products than with synthetic compounds, with
the most prevalent example being the inactivation of -lactams. -lactam antibiotics are
the most common class of antibiotics used over the past 50 years and due to its prolonged
exposure to bacteria, resistance against the -lactams has resulted from the production of
hydrolytic enzymes called -lactamases. These enzymes hydrolyze the amide bond in the
four-membered -lactam ring needed for binding to PBPs, thus rendering the antibiotic
ineffective.31
Another resistance mechanism is the modification of the drug by an antibioticaltering enzyme. A notable example is the modification of aminoglycosides (AG). There
are three types of aminoglycoside-modifying enzymes found in bacteria: an AG
acetyltransferase, an AG phosphotransferase, and an AG nucleotidyltransferase. These
modifications result in reduced binding of the aminoglycoside to the 30S ribosomal
subunit.32 The antibiotic-altering enzymes are known to work in different combinations
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and these various distributions are specific to either Gram-positive or Gram-negative
bacteria.16, 32
1.1.4 Current Antibiotic Crisis
Bacterial resistance to the current arsenal of antibiotics is an emerging threat to
society.1, 11 In recent years, the development of new antibiotics has dramatically decreased
and the pharmaceutical industry has shifted its focus towards drugs for chronic, persistent
illnesses. In addition, the cost of modifying current antibiotics to improve their overall
efficacy has a low monetary return when compared to developing the drugs for chronic
diseases. It is undeniable that antibiotic development has dramatically decreased within
the past 25 years, as illustrated in Figure 1.7.33 In fact, since 2008, only six antibiotics have
been approved by the FDA compared to the sixteen that were approved from 1983-1987.3334

There is a dire need to discover novel targets and design innovative antibiotics to combat

resistant pathogens against these targets.1, 35

Figure 1.7. Antibacterial entities approved by the Food and Drug Administration per 5year period; from Spellberg (2008).33
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1.1.5 Antibiotic Drug Design
There are several approaches to design and develop novel antibiotics. These
approaches include natural product screening, target identification and validation, highthroughput screening, structure-based drug design, virtual screening, and multitargeted
strategies.
1.1.5.1 Natural Product Screening
Natural product screening is the most successful method in the discovery of novel
antibiotics. Antibacterial agents derived from naturally occurring compounds have proven
to be effective, as unmodified natural products or natural product derivatives, account for
75% of current antibiotics36 and an estimated 40% of all medicines.37 Natural products can
be obtained from microbes and plant extracts, although many microbial and plant sources
remain unexplored.38 Natural products inherently possess more structural diversity than
purely synthetic compounds.39 Due to this diversity, the total synthesis, elaboration, and
modification of many natural products present synthetic challenges. Although antibacterial
potency can be high, the isolation of these antibiotics from their natural source runs the
high risk of rediscovering known antibiotics and requires a significant amount of effort for
a low yield of compound.37
1.1.5.2 Target Identification and Validation
There is a crucial need to identify and expand the list of potential targets for
antibacterial action. Any resistance mechanisms against any new antibacterial agents for
novel targets are unlikely to exist due to the lack of exposure to current antibiotics.40 One
way to identify targets is classic bacterial genetics which uses random mutagenesis of the
genome to observe any lethal phenotypes, and then sequencing of the genome identifies
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the mutated gene.41 Another way to identify potential targets is a comparison of a sequence
alignment between conserved bacterial genes and the human genome and looking for a
bacterial gene that lacks a human homologue.41
Once a target is identified, validation of the target will determine if it is essential
for the growth and viability of that organism. The typical approach is to construct a gene
knockout using homologous recombination.42 If the organism can survive without the gene
product, then it is not considered essential and thus is not a valid target for antibiotic
development. Once a target is validated, the next step is finding small molecules to act as
antibacterial agents against those targets.
1.1.5.3 High-throughput Screening
High-throughput screening (HTS) involves screening millions of small molecules
to determine inhibitory activity against a target.43 HTS has not been particularly successful
at identifying antibacterial agents due to the lack of whole-cell activity. In fact, Payne et
al. reported 34 pharmaceutical companies have screened 60 different targets using HTS
and failed to acquire any likely antibacterial agents. A suggested reason for the lack of
viable antibiotic candidates is the absence of chemical diversity amongst the compounds
in the screening libraries.44 It also can take many years and the synthesis of multiple
derivatives before a lead compound possesses all the necessary antibacterial and
pharmaceutical properties to become a clinically useful antibiotic.44
1.1.5.4 Structure-based Drug Design
Structure-based drug design (SBDD) is a technique that utilizes a three-dimensional
structure of the target to observe protein-ligand interactions. An analysis of how the ligand
binds to a target can reveal whether or not modifications can be made to improve the
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inhibitor.45 For example, SBDD was pivotal in the modifications to new oxazolidinones
that displayed increased potency and a better safety profile.46 As of September 16th, 2014,
there are 103,354 three-dimensional structures in the Protein Data Bank. The number of
structures will continue to increase exponentially and the vast amount of structures
available provides the tools needed for developing new antibacterial compounds.47-48
1.1.5.5 Virtual Screening
Virtual screening (VS) is a method that takes advantage of SBDD for discovering
novel antibacterial agents. VS is a computer-based method that can utilize a structure with
either an empty binding site or with a ligand bound in the active site.39 Without a ligand,
structure-based virtual screening utilizes docking algorithms to generate different positions
of a ligand as well as score those positions to estimate binding affinity.49 The ligand-based
method uses a co-structure of an inhibitor which provides for a more rapid determination
of steric and electronic features.50 The combination of virtual screening approaches can
result in the identification of a significant number of potential inhibitors without expending
the time and resources for HTS.
1.1.5.6 Multitargeted Strategies
While all the aforementioned approaches utilize single small molecules for
antibiotic development, resistance to these compounds is inevitable. Therefore, alternative
approaches to combat antibacterial resistance involving multitarget strategies are preferred.
Multitargeted chemotherapy is defined as either a combination therapy with two or more
compounds (drug cocktail), two or more chemical agents within a single tablet
(multicomponent drugs), or a single compound that targets two or more biological targets
(multitarget ligands), Figure 1.8.51

While the traditional drug cocktail is the most
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frequently used form of treatment, it is often compromised due to low patient compliance
for taking multiple medications.51 There is currently a rise in the implementation of
multicomponent drugs to simplify dosing and improve patient compliance. However,
clinicians still prefer to prescribe a combination of monotherapies because it offers greater
dose flexibility and overall lower cost for treatment. The advantage of a multi-ligand agent
is a reduced amount of protein-ligand interactions taking place throughout the cell when
compared to drug cocktails.52 The downside to the multiple ligand approach is the
difficulty in altering the ratio of activity for the different targets when using a single
compound. However, the risks and costs of development for multiple ligand drugs are no
different than that of single agent therapeutics.51

Figure 1.8. Three main clinical approaches for developing multitarget therapeutics; from
Morphy (2005).51
The design and use of hybrid, or dual-ligand, molecules is more ideal than
developing the perfect drug cocktail or multicomponent drug.53-54

The majority of

successful dual-ligand molecules consist of two protein-binding moieties joined via a linker
of an appropriate length, Figure 1.9.55 Covalently linking active biomolecules can use the
cell membrane penetration of one antibiotic to boost the penetration of the other, as well as
improve overall efficacy of both targets simultaneously.56 Dual-ligand compounds that
bind to sites whose structure is determined by more than one gene should not be susceptible
12

to single-step resistant mutations, leading to a reduced probability of forming antibiotic
resistant bacteria.35

Figure 1.9. A dual-ligand compound interacting with two proteins can induce a
biological effect; from Corson (2008).55
1.2

FATTY ACID BIOSYNTHESIS AS A TARGET FOR ANTIBIOTICS

1.2.1 Fatty Acid Synthesis
Fatty acid biosynthesis (FAS) is one of the most important and fundamental
metabolic pathways in nature and is critical to bacterial viability.57 The enzymes of the
FAS pathway are divided into two distinct arrangements: type I or type II. The proteins of
type I fatty acid synthase (FASI) in eukaryotes are expressed on a single large,
multifunctional polypeptide containing domains for each enzyme.58 Type I FAS enzymes
are found most commonly in mammals, fungi, and some mycobacteria.57, 59 In contrast,
type II fatty acid synthase (FASII), found in the plastids of plants60 and most bacteria,
contains individual proteins that are encoded by discrete genes with the reaction
intermediates being carried through the cytosol via a thioester on the acyl carrier protein
(ACP).57, 61-62 The steps in the FAS pathway are identical in mammals and bacteria, so the
reactions catalyzed by the enzymes in the FAS pathway are the same. However, inhibitors
can be produced to selectively target the bacterial system enzymes, as the protein sequences
and active site arrangements are different in the enzymes compared to the human forms.59,
63
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The enzymes of fatty acid biosynthesis are targets for the development of novel
antibacterial agents, as fatty acids are crucial for membrane biogenesis and cell
proliferation.62 The enzymes and proteins involved with FASII consist of highly conserved
protein sequences and are often encoded in clusters.58 The ability to isolate the enzymatic
activity of each protein in this pathway also makes this an ideal system for studying
potential antibacterial agents.59 The acc genes initiate the entire pathway of saturated fatty
acid synthesis and encode the four-subunit, biotin-dependent enzyme acetyl-CoA
carboxylase (ACC), which catalyzes the first committed step in this pathway. The fab
(fatty acid biosynthesis) genes are responsible for encoding the majority of the proteins of
this pathway.59 The enzymes encoded by these genes are desirable targets for therapeutic
developments, Figure 1.10.63

Figure 1.10. Pathway of fatty acid biosynthesis (FAS). Known inhibitors of the respective
steps are shown; from Heath (2001).58
1.2.2

Fatty Acid Synthesis Inhibitors
Multiple FAS inhibitors have been developed as antibacterial agents, with the most

well-known example being triclosan. Triclosan acts as a slow-binding inhibitor against
enoyl-ACP reductase, encoded by the fabI gene.58,63 Triclosan was originally patented as
a herbicide, but was revealed to possess broad-spectrum antibacterial properties.64 The
14

antibacterial power and safety of triclosan has led to its inclusion in many consumer
products including antibacterial soaps, plastics, toothpaste, and detergents.

Many

structurally related analogues of triclosan, including hexachlorophene (Figure 1.11), also
possess antimicrobial activities.58 Early studies showed that triclosan and hexachlorophene
displayed a mode of action causing E. coli to release cytoplasmic material following a drug
treatment.64 This indicated a non-specific disruption and led to the initial assumption that
bacteria cannot become resistant to non-specific biocides.58 Despite a non-specific mode
of action, the widespread use of triclosan is now presenting a potential health risk as
resistance is developing against clinically important pathogens.65

For example, the

pathogen P. aeruginosa is resistant to triclosan as a result of its multidrug efflux pumps.6667

Figure 1.11. Structures of triclosan and hexachlorophene, as well as other compounds
known to inhibit fatty acid biosynthesis.
Two other antibacterial compounds which inhibit FAS enzymes are cerulenin and
thiolactomycin.59

Cerulenin (CER) was the first compound identified to inhibit the
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elongation condensing enzymes -ketoacyl-ACP synthase I and II, encoded by the genes
fabB and fabF, respectively.63 CER occupies the hydrophobic channel in the enzyme
where the growing chain of acyl-ACP would bind. However, CER is unlikely to ever
become clinically useful due to its instability, poor pharmacological properties, and weak
inhibition of mammalian fatty acid synthesis.59 Thiolactomycin (TLM) was isolated from
soil samples and was shown to have potent antibiotic activity against different bacterial
species both in vitro and in animal studies, while lacking activity against FASI enzymes.59
In contrast to CER, TLM binds to the malonyl-ACP binding site of -ketoacyl-ACP
synthase, which is found on the other side of the active site from the acyl-ACP channel.63
Even though TLM only has modest antibacterial activity, it exhibits broad-spectrum
activity against important pathogens, such as Mycobacterium tuberculosis and malaria.68
With a majority of the enzymes found in FASII being essential for bacterial viability,
they are ideal targets for antibacterial drugs. However, there are currently no inhibitors
being utilized clinically as antibacterial agents against the enzymes of bacterial acetyl-CoA
carboxylase. Plants utilize the FASII system and plant ACC is a widely used target for
herbicides, which confirms this step in the FAS pathway as a viable target for the
development of novel antibacterial agents.63, 69
1.3 ACETYL-COA CARBOXYLASE
Acetyl-CoA carboxylase (ACC) is a multicomponent enzyme that catalyzes the first
committed step in fatty acid synthesis and is found in animals, plants, and bacteria.70
Acetyl-CoA carboxylase is made up of three subunits by four separately expressed
proteins. They include a homodimeric biotin carboxylase (BC), a biotinylated biotin
carboxyl carrier protein (BCCP), and an 22 heterotetrameric carboxyltransferase (CT).
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The genes for BC (accC) and BCCP (accB) are cotranscribed from an accBC mini-operon,
while the genes for the - and -subunits of CT are encoded by accA and accD,
respectively.71-73 ACC was the first in a new class of enzymes to be recognized that use
biotin as a prosthetic group.74 The biotin is covalently attached to a lysine residue (Lys122;
E. coli numbering) found on the biotin carboxyl carrier protein.75

Isolated biotin

carboxylase and carboxyltransferase can both utilize free biotin, i.e. not attached to BCCP,
as a substrate making this enzyme an ideal system for studying biotin-dependent
reactions.76-77
Acetyl-CoA carboxylase catalyzes the conversion of acetyl-CoA to malonyl-CoA via
two half-reactions.

In the first half-reaction, BC catalyzes the ATP-dependent

carboxylation of the BCCP via a carboxyphosphate intermediate. In the second halfreaction, CT transfers the CO2 group from carboxybiotin onto the acceptor molecule,
acetyl-CoA, to generate malonyl-CoA, Figure 1.12.78

Figure 1.12. Acetyl-CoA (ACC) mechanism showing the two half-reactions catalyzed by
biotin carboxylase (BC) and carboxyltransferase (CT).
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1.3.1 Biotin Carboxylase
The structure of biotin carboxylase (BC) from E. coli was solved by Waldrop et al.
in 1994 and was the first structure of a biotin-dependent carboxylase. BC is a homodimer
and each monomer consists of 449 amino acid residues that are divided into three domains:
an N-terminal domain, a B-domain or ATP-grasp domain, and a C-terminal domain.79
Each monomer contains a complete active site as opposed to the active site being shared
between residues or interfaces of the monomers.79 The biotin carboxylase from E. coli is
also similar in structure to the BC of P. aeruginosa, as well as other BC domains of biotindependent carboxylases.80-82
The three substrates of the BC reaction: ATP, biotin, and bicarbonate, follow a
sequential kinetic mechanism, meaning that all substrates must bind to the enzyme before
a product can be released.83 Kinetic data also indicated that substrate addition was ordered
with ATP binding first, followed by bicarbonate and then biotin, Figure 1.13.84

Figure 1.13. Structural changes at the ATP-binding site of PaBC upon the binding of the
ATP analog AMPCP. Ribbon representation of the protein coordinates of PaBC in the apo
form is colored in green. Ribbon representation of the PaBC/AMPCP complex is colored
in magenta; from Mochalkin (2008).80
When ATP, or an ATP analog binds to the active site, the ATP-grasp domain rotates 45°
to close down on top of the substrate and hold it in the active site, Figure 1.13.85-86 This is
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considered the closed conformation and can be seen in crystal structures solved with
ligands, including BC bound to all three substrates.80, 87
Biotin carboxylase has been shown to exhibit substrate-induced synergism, where
the activity of BC is increased 1100-fold when biotin is bound.88,70 Upon the binding of
biotin, ATP will assume the more favorable extended conformation to allow for formation
of the carboxyphosphate intermediate and subsequent carboxylation of biotin.70 Evidence
for the different binding modes of ATP can be seen in structures of AMPPNP, an ATP
analog, bound to BC. The structure of AMPPNP bound to E. coli BC showed the phosphate in a curled conformation, while the structure of Staphylococcus aureus BC
bound with AMPPNP revealed an extended conformation, Figure 1.14.80

Figure 1.14. Superimposed AMPPNP in crystal structures of SaBC and EcBC.
SaBC/AMPPNP structure is colored in red and EcBC/AMPPNP structure is colored in
blue. SaBC residues involved in interactions with the ligand are shown in sticks; from
Mochalkin (2008).80
The active sites of BC have also been shown to display half-sites reactivity, or an
extreme form of negative cooperativity, where the active sites alternate catalyzing the
reaction.89 In order to demonstrate this, hybrid dimers were created where one monomer
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was wild-type BC and the other monomer was an inactive mutant. The mutant dimers were
expected to display 50% of wild-type activity, but the overall activity ranged from 0.43.6%, revealing the mutant monomer was exerting a dominant-negative effect on the wildtype monomer.89 This is indicative that the two active sites undergo oscillating cycles of
catalysis whereby when one monomer of BC is releasing the product, the other monomer
is binding substrates for catalysis. The structural evidence of the oscillating catalytic
mechanism was observed in a crystal structure where one BC monomer was bound to
ADPCF2P (an ATP analog) in the closed conformation and the other monomer was in the
open conformation with no ligand in the active site, Figure 1.15.80

Figure 1.15. EcBC dimer containing the ADPCF2P molecule bound to one subunit of the
enzyme. The subunit with bound ATP analog is in closed conformation and colored in
blue. Ribbon representation of the unliganded subunit of EcBC is in open conformation
and colored in pink. The backbone structure of the EcBC subunit containing ADPCF2P is
superimposed on the unliganded subunit for comparison and is shown in blue as a backbone
representation; from Mochalkin (2008).80
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1.3.2 Biotin Carboxyl Carrier Protein
1.3.2.1 Utilization of Biotin for Catalysis
The biotin carboxyl carrier protein (BCCP) uses the vitamin biotin for the ACC
reaction. Biotin is a bicyclic compound composed of an ureido ring, a tetrahydrothiophene
ring, and a valeric acid side chain.85 There are eight stereoisomers of biotin, but D-(+)biotin is the only active form found in nature and is only active when attached to certain
metabolic enzymes (Figure 1.16).75, 90-91 Biotin is the major cofactor found in metabolic
processes involving carbon dioxide.

Figure 1.16. Active form of biotin, D-(+)-biotin.
The biotin cofactor is covalently attached to BCCP. Full length biotin carboxyl
carrier protein has a molecular weight of 16.7 kDa, although early purification of BCCP
yielded a range of molecular weights that were attributed to oligomerization or proteolytic
cleavage of the full length protein.92 A system was later developed to overexpress and
purify the last 87 residues of BCCP (BCCP87).93 BCCP87 can be biotinylated and has
been shown to have an 8000-fold and 2000-fold greater catalytic efficiency than biotin in
the BC and CT reactions, respectively.94
1.3.2.2 Structure of BCCP
The structure of E. coli BCCP is composed of two domains, an N-terminal domain
and a C-terminal domain. The crystal structure of the C-terminal domain of E. coli BCCP
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was first solved in 1995 by Athappilly et al. and contained two sets of four antiparallel strands.95 In 1997, Yao et al. solved the NMR structure of apo-BCCP87 (i.e., without
biotin attached) and the NMR structure of holo-BCCP87 was solved shortly thereafter and
both NMR structures showed no difference compared to the crystal structure.96 The Cterminal domain of BCCP is highly conserved and contains the lysine targeted for
biotinylation in an AMKM motif that is highly conserved.75

The AMKM motif is

biotinylated at the Lys122 (E. coli numbering), and was found in a -hairpin turn that
extends out from the body of the C-terminal domain (Figure 1.17).75, 97 The orientation of
the residues in the C-terminal domain of BCCP affects efficient use of the protein as a
substrate, as the C-terminal domain is thought to undergo a structural change upon
biotinylation.98

Figure 1.17. Ribbon drawing of the E. coli BCCP87 NMR structure with the biotinbinding Lys122 residue shown on the -hairpin turn of the C-terminal domain; from Yao
(1997).97
The structure of E. coli holo-BCCP still has not been crystallized, most likely due
to a pro-ala rich linker region between the domains of BCCP that causes the N-terminal
domain to be flexible.99 Li et al. postulated the N-terminal domain of BCCP was involved
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in the interaction of BCCP with the other subunits of ACC.71 However, a recent crystal
structure of the E. coli BC-BCCP complex showed the N-terminal domain was not
involved in the interaction between these two subunits.100
A unique feature observed with E. coli BCCP is a “thumb” region that extends out
from the body of the C-terminal domain, Figure 1.18. This thumb region was shown to be
essential for bacterial viability of E. coli as deletion of the thumb region in BCCP mutants
prevented growth.101 The mechanism for this phenomenological result is not known. It is
clearly not needed for catalysis because BCCP from other species lack a thumb, Figure
1.18.100-101 Additionally, this region does not appear to be involved with the biotinylation
reaction as proteins that lack a thumb region can still be biotinylated by biotin protein
ligase.102

Figure 1.18. Overlay of E. coli BCCP (purple) with the BCCP domain from human acetylCoA carboxylase (yellow) and the 1.3S subunit of transcarboxylase (green). The -hairpin
turn is labeled and the unique thumb region of the E. coli BCCP is shown pointing upwards;
from Broussard (2013).100
1.3.2.3 Biotin Protein Ligase
Biotin protein ligase (BPL), or holocarboxylase synthetase, is a highly conserved
enzyme and is responsible for attaching the biotin onto the appropriate lysine residue via
two half-reactions, Figure 1.19.75 In the first half-reaction, BPL catalyzes the formation of
biotinoyl-5′-AMP from the substrates, biotin and ATP. During the second half-reaction,
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biotin is transferred from biotinoyl-5′-AMP to form an amide bond between the -amino
group of lysine and the carboxylic acid on the valeric acid side chain of biotin.75 BPL is
able to selectively biotinylate biotin-dependent enzymes from many bacterial species,
although in E. coli, acetyl-CoA carboxylase is the only carboxylase that undergoes this
biotinylation reaction since ACC is the only biotin-dependent enzyme found in E. coli.103104

Figure 1.19. The biotin protein ligase (BPL) reaction; adapted from Chapman-Smith
(1999).75
1.3.3 Carboxyltransferase
Carboxyltransferase was the last of the ACC subunits to be crystallized. The
carboxyltransferase domain of yeast ACC was first crystallized in 2003 by Zhang and
coworkers.105 The crystal structures of S. aureus and E. coli CT were crystallized by Bilder
et al. in 2006. The structure confirmed the bacterial form of CT exists as an 22
heterotetramer, Figure 1.20, which was first suggested by Guchhait et al. in 1974.106-107
This observation was in contrast to the yeast CT structure which existed as a dimer, with
each monomer containing two domains. These two domains appeared to mimic the
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individual - and -subunits found in bacterial CT.85, 105 The active sites of bacterial CT
are formed at the interface of the - and -subunits, where the -subunit binds biotin and
the -subunit binds acetyl-CoA.

Figure 1.20. The 22 heterotetrameric structure of carboxyltransferase with the subunit in yellow and the -subunit in purple; from Bilder (2006).106
An interesting feature of this active site is that both the - and -subunits contain a
symmetrical core fold where the binding of these substrates occurs, placing
carboxyltransferase in the crotonase superfamily of enzymes, Figure 1.21, (A).106, 108 The
members of this superfamily of enzymes all catalyze reactions that involve enolate
anions.109 In order to stabilize these oxyanions, two peptidic -NH groups form an oxyanion
hole allowing hydrogen bonding from the peptidic protons to the enolate anions. The
peptidic -NH groups responsible for hydrogen bonding are found at the N-terminus of an
-helix, where the helix dipole helps provide an overall positive charge for anion
stabilization.85 In E. coli, the putative active site residues involved in the formation of
these oxyanion holes are Gly204 and Gly205 in the -subunit and Gly206 and Gly207 in
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the -subunit and are used to stabilize the enolate and imidate anions in acetyl-CoA and
biotin generated during catalysis, respectively, Figure 1.21, (B).

106

Figure 1.21. (A) The structure of the - and -subunits of carboxyltransferase with the
crotonase-fold motif highlighted in blue and the adjacent glycine residues that form the
oxyanion holes highlighted in red; from Waldrop (2011).108 (B) The oxyanion holes
generated from peptidic amine groups in the - and -subunits of carboxyltransferase.
The crystal structures of E. coli and S. aureus also revealed a four-cysteine zinc
finger domain on the N-terminus of the -subunit, which had never been observed before
with the eukaryotic carboxyltransferases, Figure 1.22.85, 106 The amino acids that constitute
and surround this domain have a positive electrostatic surface potential, while the rest of
the protein has an overall negative electrostatic surface potential.106, 110 A common feature
associated with zinc finger domains is their ability to bind nucleic acids. Benson et al.
showed that E. coli CT was indeed able to bind DNA in a non-specific manner.110 The
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study also revealed that not only does DNA inhibit CT activity, but the binding of the CT
substrates (malonyl-CoA and biocytin) inhibit the binding of DNA.110 Mutational analysis
of the zinc finger domain displayed a substantial decrease in activity when only one
cysteine was mutated, while more than one mutation resulted in complete loss of activity.111

Figure 1.22. The four-cysteine zinc finger found on the N-terminus of the -subunit of
carboxyltransferase; from Meades (2010).111
1.3.4 Regulation of Bacterial ACC
The reaction catalyzed by acetyl-CoA carboxylase is the rate-limiting and
committed step in fatty acid biosynthesis.112 Fatty acid synthesis accounts for 94% of ATP
consumption for membrane biogenesis and inefficient regulation of this pathway would
result in an unnecessary use of cellular energy.113
The BC-BCCP genes may be transcriptionally regulated. The overexpression of
BCCP down-regulated expression of the chromosomal accBC operon and more
specifically, the overexpression of the first 44 residues of the N-terminal of BCCP
decreased transcript levels.73 In addition, James and Cronan replaced the promoter of the
accBC mini-operon with the promoter from the lactose operon and found expression of the
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accBC gene increased by 5-fold in comparison to transcription levels in the presence of the
wild-type promoter. This result led to the conclusion that BCCP, and more specifically the
N-terminal domain of BCCP, is involved in autoregulating the transcription of the accBC
operon and is likely the method of regulation in many bacterial species due to the
cotranscription of these two genes being highly conserved.73 In contrast, the accA and
accD genes encoding the - and -subunits of CT, respectively, are expressed in gene
clusters on opposite sides of the E. coli chromosome.113 Both genes are transcribed in a
clockwise rotation and could be co-regulated, although there is no data to support this.71,
113

There are different ways that acetyl-CoA carboxylase is regulated. For example,
Meades et al. has recently shown that CT can regulate its own translation by specifically
binding to the mRNA that codes for the - and -subunits of CT.111 Acetyl-CoA competes
with its own mRNA for binding to the active site of CT. This allows for CT to work as a
“dimmer switch” for its own translation by detecting the cellular levels of acetyl-CoA.111
For instance, when there is an increase in cellular growth rates and the intracellular levels
of acetyl-CoA are high, CT is displaced from its mRNA allowing for the translation of CT
and subsequent production of malonyl-CoA.111 Additionally, a recent study by Broussard
et al. has shown that the BC reaction displays substrate synergism with acetyl-CoA; in
other words, the three components of ACC do not undergo catalysis unless acetyl-CoA is
also present in order to avoid wasteful hydrolysis of ATP.114 The ACC complex is also
subject to negative feedback inhibition by the end products of fatty acid synthesis, the long
chain acyl-ACPs.58

28

1.4 BACTERIAL ACETYL-COA CARBOXYLASE AS A NOVEL TARGET FOR
ANTIBIOTICS
ACC catalyzes the first committed step in fatty acid synthesis and is essential for
bacterial viability, making ACC a promising target for the development of antibiotics with
novel modes of action.115-116 Acetyl-CoA carboxylase is highly conserved among bacteria
therefore novel antibiotics have the potential to behave as broad-spectrum agents. There
are currently no examples of ACC inhibitors being clinically used as antibacterial agents.
The recent discovery of small molecule inhibitors of ACC present potential clinical
antibiotics.117
1.4.1 Antibacterial Agents of Biotin Carboxylase
Biotin carboxylase is the target for three different types of antibacterial compounds:
pyridopyrimidines118, aminooxazoles119 and benzimidazole-carboxamides115.
1.4.1.1 Pyridopyrimidines
The pyridopyrimidines were the first class of antibacterial agents found to inhibit
BC. Miller et al. utilized bacterial whole-cell screening on a library of 1.6 million
compounds originally designed to target eukaryotic tyrosine kinases.118 While screening
these compounds, they discovered a class of pyridopyrimidines that exhibited antibacterial
activity.118

The target of the pyridopyrimidines was determined by generating

spontaneous-resistant mutations in bacteria.

The strains responsible for exhibiting

resistance were sequenced and the resistance-conferring gene was mapped back to accC,
which encodes the BC component of ACC. The resistance mutation resulted in the
isoleucine at position 437 being replaced with a threonine and this mutation was found to
reside in the ATP-binding site of BC.80, 118
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The pyridopyrimidines were bactericidal in vitro as well as in vivo against Gramnegative pathogens, such as E. coli and Haemophilus influenzae, as well as the Grampositive S. aureus. However, the MIC values were higher for Gram-positive pathogens
indicating selectivity for Gram-negative BC. The selective action of the pyridopyrimidines
for Gram-negative bacteria can be traced back to the I437T mutation that was used to
identify the target. Biotin carboxylase in Gram-positive bacteria naturally contain a
threonine at that position. Structural analysis of pyridopyrimidine 1 bound to the I437T
mutant in E. coli revealed the threonine caused a decrease in antibacterial activity due to
loss of hydrophobic contacts as well as reduced shape complementarity with the
inhibitor.118-120 The pyridopyrimidines were also revealed to be selective for bacterial BC
over eukaryotic BC.118
1.4.1.2 Aminooxazoles
To expand on the findings of the pyridopyrimidines, Mochalkin et al. utilized
virtual screening and fragment-based drug discovery to identify novel inhibitors for biotin
carboxylase. First, they used ligand-based virtual screening using pyridopyrimidine 1
(Figure 1.23A) as a starting point for screening a library of 2.2 million compounds to
identify structures with similar shapes and surface electrostatics as the lead inhibitor.117, 119
After in vitro testing of 525 compounds identified in the screen, a total of 48 compounds
displayed 50% inhibitory concentration (IC50) values of less than 10 M.
In addition, Mochalkin et al. used fragment-based screening on a library of 5,200
fragments to yield 142 compounds that exhibited significant inhibition of BC.
Superimposition of the structures revealed the pharmacophore features that were important
for binding in the ATP-binding site of BC.117 For example, fragment 2, Figure 1.23, (A),
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was found to be an inhibitor of BC and shared similar binding features with
pyridopyrimidine 1.119 A comparison of structures shows that fragment 2 contains an exocyclic amine group on the oxazole ring, analogous to the exo-cyclic amine in the
pyrimidine ring of compound 1. Structural analysis confirmed the aminooxazole fragment
interacts in the same manner and with the same active site residues in BC as the
pyridopyrimidines, Figure 1.23, (B).119-120

Figure 1.23. (A) Pyridopyrimidine BC inhibitor 1 and fragment hit 2. Selected
pharmacophore features essential for binding interactions shown in following colors: cyan
(hydrogen bond acceptors) and pink (hydrogen bond donors). (B) Binding modes of
compound 1 and fragment 2 to the ATP-binding site of EcBC determined by X-ray
crystallography; from Mochalkin (2009).119
While fragment-based screening allows for testing of large libraries of compounds,
these compounds usually display low binding affinity to the target; therefore, fragment-tolead optimization was utilized to discover more potent inhibitors. The use of fragment
growing, merging, and morphing was used to identify compounds with a much higher
affinity for BC. Even though pyridopyrimidine 1 is a potent inhibitor (Ki = 5 nM), the
aminooxazoles were more amenable to synthetic elaboration and thus were used in these
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studies. The aminooxazole moiety from fragment 2 provided an “anchor” for binding to
the ATP site while extending fragment 2 out into the active site allowed for increased
interaction with hydrophobic residues that led to increased potency without compromising
binding efficiency.119
This fragment-based approach led to different aminooxazole analogs (compounds
3-5, Figure 1.24) that were synthesized and analyzed for inhibitory and antibacterial
activity.119 Fragment 3 showed a 20-fold increase in potency over starting fragment 2 while
fragment 4 containing the dibenzylamide side chain had a net 200-fold increase in potency
over fragment 2. The selection of a more electron-rich side chain led to the generation of
fragment 5 with an impressive 3000-fold increase in potency over fragment 2. The more
potent inhibitors of BC, fragments 4 and 5, displayed antibacterial activity against effluxpump-deficient H. influenzae and E. coli.119-120 However, fragment 5 overall displayed
whole-cell activity that was markedly lower than fragment 4. This highlights a major
challenge when developing new antibacterial agents in that target potency does not
necessarily correlate to whole-cell antibacterial activity.119

Fragments 4 and 5 also

displayed a reduction in antibacterial activity against bacteria with the I437T mutation,
similar to pyridopyrimidine 1.119

Figure 1.24. BC inhibitor fragments 3-5.
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1.4.1.3 Benzimidazole-carboxamides
Around the same time the pyridopyrimidines and aminooxazoles were being
discovered, a group at Schering-Plough was developing their own class of BC inhibitors,
the benzimidazole-carboxamides.115 Cheng et al. utilized HTS to identify a group of
compounds that displayed inhibitory activity against BC. Additional SBDD and computerguided modeling of the initial hits generated a series of benzimidazole-carboxamide
derivatives, for example benzimidazole 6, Figure 1.25, (A).

X-ray crystallography

confirmed benzimidazole 6 bound in the ATP-binding site of BC, Figure 1.25, (B). The –
NH2 of benzimidazole 6 was found to interact with both Glu201 and Lys202, which are the
same residues that interact with the exo-cyclic amines found in both the pyridopyrimidines
and the aminooxazoles. This indicates the primary –NH2 groups are an essential structural
moiety for enzyme recognition and binding. The benzimidazoles also inhibited a broadspectrum of pathogenic bacteria and were shown not to inhibit eukaryotic ACC.115

Figure 1.25. (A) Structure of benzimidazole 6. (B) Structure of benzimidazole 6 bound in
the BC active site; from Cheng (2009).115
1.4.2 Antibacterial Agents of Carboxyltransferase
In contrast to the biotin carboxylase, there is only one known class of antibacterial
agents known to inhibit carboxyltransferase, the natural products andrimid and moiramide
B, Figure 1.26. Andrimid was isolated and characterized from an Enterobacter sp. in an
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intracellular symbiont found in the brown planthopper, Nilaparvata lugens.121 A few years
later, Needham et al. isolated marine microorganisms from their habitats and screened
them for antibiotics with antibacterial activity.122 Through screening of these marine
organisms, an isolate of the bacterium Pseudomonas fluorescens was acquired and an
extract from this marine species displayed strong inhibition against methicillin-resistant S.
aureus (MRSA).

Fractionation of the extract resulted in the identification of four

metabolites: andrimid and moiramides A-C (Figure 1.26) with only andrimid and
moiramide B exhibiting any antibacterial activity.122

Figure 1.26. Structures of the natural products andrimid and moiramides A-C.
Biological studies revealed that andrimid and moiramide B both showed broadspectrum in vitro antibacterial activity, with moiramide B being more potent.122-123 Prior
synthesis of andrimid revealed the pyrrolidinedione fragment containing the 4S-methyl
substituent to be essential for activity, as removal of the methyl group abolished activity.124125

Moiramides A and C were both inactive in regards to MRSA and other species, which

further reiterates the strict structural conformation of the pyrrolidinedione fragment;
moiramide A lacks a pyrrolidinedione unit completely while moiramide C contains a 3Rhydroxyl substitution on the pyrrolidinedione ring.122, 126
The target for moiramide B was determined by Freiberg et al. to be the
carboxyltransferase enzyme of acetyl-CoA carboxylase.
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Moiramide B displayed

competitive inhibition against malonyl-CoA (Kis = 5 nM) and noncompetitive inhibition
against biocytin.123 The generation of various resistant mutants of S. aureus revealed single
amino acid mutations in not only the subunit of CT, but also the -subunit which
validated moiramide B targets the CT component of ACC.116, 123 Studies also revealed a
lack of inhibition against eukaryotic ACC, indicating selectivity for the prokaryotic form
of the enzyme.123 Structure-activity relationship (SAR) studies of moiramide B revealed
that the fatty acid chain and the pyrrolidinedione moiety play two different roles in binding
to the target. Variations to the fatty acid side chain showed it was not pivotal to binding
while limited modifications to the pyrrolidinedione head group were tolerated. Analogs
with either bulky, hydrophobic groups on the pyrrolidinedione nitrogen or modification of
the (4S)-methyl group displayed a significant decrease or total loss in antibacterial
activity.125

A crystal structure of these potent natural products in complex with

carboxyltransferase would further validate the mode of action.
1.5

PURPOSE OF DISSERTATION
The identification of inhibitors targeting each enzyme of ACC has the potential to

generate a dual-ligand inhibitor for this multicomponent enzyme. Aminooxazole 4 is
amenable to synthetic variations on the dibenzylamide side chain without affecting the
crucial moieties necessary for binding in the ATP-binding site of biotin carboxylase.
Likewise, the acyl side chain is not required for moiramide B to bind to
carboxyltransferase, allowing for modifications to this portion of the molecule. This allows
for appropriate functional groups to be placed on each known inhibitor to be chemically
modified into a dual-ligand inhibitor connected via a linker segment. A designed dualligand inhibitor incorporating these known ACC inhibitors could ultimately generate an
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inhibitor that behaves as a broad-spectrum antibacterial agent. A dual-ligand inhibitor can
also possess an overall tighter affinity than individual agents which ultimately leads to
using less antibiotics to generate the same effect; therefore, bacteria are less likely to
develop resistance mechanisms. The design and synthesis of dual-ligand inhibitors for
ACC and the biological testing of their potency will determine the overall best model for
generating multitarget therapeutics to combat resistant pathogenic bacteria.56
The ability to synthesize the natural product moiramide B paves the way for further
characterization and determination of the mode of action for this class of antibiotics. The
construction of moiramide B proceeds in a head-to-tail fashion, starting with the
pyrrolidinedione head group and ending with the attachment of the unsaturated acyl chain.
By isolating moiramide B into molecular fragments, the function of those fragments with
respect to the inhibition of carboxyltransferase and the antibacterial properties can be
determined. The availability of moiramide B in milligram quantities also yields enough
compound to determine the three-dimensional structure of moiramide B bound to
carboxyltransferase and reveal the mechanism of action.
1.6
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CHAPTER 2: DESIGN, SYNTHESIS, AND ANTIBACTERIAL PROPERTIES
OF DUAL-LIGAND INHIBITORS OF ACETYL-COA CARBOXYLASE1
2.1

INTRODUCTION
In 2013, the CDC issued an alarming report on the dramatic rise in antibiotic

resistant bacteria.1 The report noted that over 2 million people per year are afflicted with
bacterial infections resistant to at least one antibiotic. In addition, there are 23,000 deaths
per year directly attributable to antibiotic resistant infections.

One of the core

recommendations in the report for combating this public health crisis is the development
of new antibiotics. The current arsenal of antibiotics is directed at only 30-40 molecular
targets. Thus, there is a pressing need to develop antibiotics against novel targets. Fatty
acid biosynthesis is an essential metabolic pathway in both eukaryotes and prokaryotes
and since fatty acids are required for membrane biogenesis in bacteria, fatty acid
synthesis is an attractive pathway to focus on for antibiotic development.2-4
The first committed and regulated reaction in fatty acid biosynthesis is catalyzed
by the multifunctional enzyme acetyl-CoA carboxylase (ACC).5 The overall reaction
catalyzed by ACC is shown in Scheme 2.1. ACC requires the vitamin biotin, which is
covalently attached to the biotin carboxyl carrier protein (BCCP). In the first halfreaction, catalyzed by biotin carboxylase (BC), BCCP-biotin is carboxylated in an ATPdependent manner where bicarbonate is the source of CO2. The second half-reaction,
catalyzed by carboxyltransferase (CT), involves the transfer of the carboxyl group from
BCCP-biotin to acetyl-CoA to form malonyl-CoA. In eukaryotes, the three proteins that
comprise ACC form domains on a single polypeptide chain,6 whereas in prokaryotes,
1

Reproduced with permission from Journal of Medicinal Chemistry, submitted for
publication. Unpublished work copyright 2014 American Chemical Society.
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they are encoded as three separate proteins.7 The bacterial forms of biotin carboxylase
and carboxyltransferase retain their activity when isolated from the other components and
only utilize free biotin as a substrate.4-5 With respect to antibacterial development, the
different arrangement of the three protein components of ACC between eukaryotes and
prokaryotes provides potential for the design of inhibitors that selectively target the
bacterial system.3-4

Moreover, the three components of ACC are highly conserved

among bacterial species, increasing the likelihood of developing broad spectrum
antibacterial agents.7-8

Scheme 2.1. Reactions catalyzed by acetyl-CoA carboxylase (ACC).
Both the biotin carboxylase and the carboxyltransferase components of acetylCoA carboxylase have served as targets for antibacterial agents. Miller et al. discovered
that the antibacterial properties of the pyridopyrimidine class of molecules was due to the
inhibition of biotin carboxylase.9 The pyridopyrimidines (e.g. compound 1, Figure 2.1)
bound in the ATP binding site of bacterial biotin carboxylase but did not inhibit human
biotin carboxylase.

The pyridopyrimidines were not readily amenable to synthetic

modifications, so Mochalkin et al. used fragment and virtual screening to identify a series
of aminooxazole derivatives (e.g. compound 2 in Figure 2.1) that also inhibited biotin
carboxylase by binding in the ATP binding site.10

In common with the

pyridopyrimidines, the aminooxazole derivatives were selective inhibitors of the
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bacterial, but not human, biotin carboxylase, and were shown to exhibit potent
antibacterial activity against efflux-compromised Gram-negative pathogens.10

Figure 2.1. Pyridopyrimidine 1 and aminooxazole 2, inhibitors of biotin carboxylase.
In contrast to biotin carboxylase, there is only one known class of molecules that
inhibits the carboxyltransferase component of acetyl-CoA carboxylase and also possesses
antibacterial activity. While the biotin carboxylase inhibitors are invariably of synthetic
origin, the carboxyltransferase inhibitors are natural products. The antibacterial activity
of andrimid (3) and moiramide B (4) (Figure 2.2) had been known for at least 10 years as
broad spectrum antibacterial agents.11 Freiberg et al. discovered that the molecular target
for andrimid (3) and moiramide B (4) was the carboxyltransferase subunit of ACC.11-12
Structure-activity relationship (SAR) studies revealed that the pyrrolidinedione head
group was essential for enzyme inhibition and antibacterial activity, while the fatty acid
chain is not required.13 Moiramide B (4) was found to have an inhibition constant of 5
nM and exhibited competitive inhibition versus malonyl-CoA.12,

14,2

Moiramide B (4)

inhibited carboxyltransferase from both Gram-negative and Gram-positive organisms,
which is consistent with its broad spectrum activity.

In common with the biotin

carboxylase inhibitors, moiramide B (4) did not inhibit human acetyl-CoA carboxylase.12
2

The activity of carboxyltransferase is measured in the reverse or non-physiological
direction where malonyl-CoA and biocytin (a biotin analog) are the substrates. The
formation of the product acetyl-CoA is detected using the coupling enzymes, citrate
synthase and malate dehydrogenase.
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Figure 2.2. Andrimid (3) and moiramide B (4), inhibitors of carboxyltransferase.
Despite the fact that both biotin carboxylase and carboxyltransferase have been
validated as unique targets for antibacterial development through the discovery of
selective antibacterial inhibitors, both targets suffer from high potential for spontaneous
resistance through individual target-based mutations.

One approach to decrease the

likelihood of developing resistance is to make a single molecule that incorporates
inhibitory motifs for both the biotin carboxylase and carboxyltransferase enzymatic
activities.

The potential lower frequency of resistance against such a dual-ligand

inhibitor is explained by considering the genetic arrangement of ACC.

Biotin

carboxylase is a homodimer encoded by the accB gene, while carboxyltransferase is a
heterotetramer with - and -subunits encoded by accA and accD, respectively. The
accA and accD genes encoding the subunits of carboxyltransferase are not genetically
linked.15 This genetic arrangement is commonly found in both Gram-negative and Grampositive bacteria. Thus, one would predict that nonessential missense mutations would
have to arise in three different genes in order for the bacteria to become resistant to a
molecule targeting both enzymes simultaneously.
While the use of dual-ligands for lowering the frequency of resistance is well
documented,16-19 most examples of dual-ligands as antibacterial agents involve inhibitors
that target two enzymes that either do not interact and/or are not related metabolically.
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Thus, a dual-ligand inhibitor of ACC would represent a departure from previous practice.
In fact, a dual-ligand inhibitor of ACC is a particularly attractive strategy for inhibition of
the enzyme in light of recent studies that have demonstrated that all three protein
components (biotin carboxylase, BCCP and carboxyltransferase) must form a complex in
vivo for activity.20 On this background, we report the first step toward dual-ligand
inhibition of ACC by linking the aminooxazole 2 inhibitor of biotin carboxylase to the
carboxyltransferase inhibitor, moiramide B (4), and characterizing the inhibitory and
antibacterial properties.
2.2

RESULTS AND DISCUSSION

2.2.1 Design Strategy
In order to generate dual-ligand inhibitors incorporating these known inhibitory
motifs (compounds 5 and 6, Figure 2.3), we needed to identify loci in each inhibitor
where we could attach a metabolically stable linker without compromising binding and
biological activity.

A suitable, stable functional group needed to be placed on the

dibenzylamide side chain of aminooxazole 2 (Figure 2.1). We decided to incorporate a
hydroxyl group at the para position of one of the benzene rings (compound 13, Scheme
2.2). This modification was not expected to affect binding to biotin carboxylase, since it
is the aminooxazole moiety that is responsible for interaction with the ATP binding site.10
In the case of moiramide B (4) (Figure 2.2), it has been shown that the fatty acid side
chain can be significantly modified with retention of biological activity.13 We thereby
elected to replace this fatty acid chain with a lipophilic linker at the N-terminus of the phenylalanine residue in the naturally-occurring, biologically active pseudopeptide
(Figure 2.3).
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Finally, we needed to choose linkers to covalently connect the aminooxazole and
moiramide components of the dual-ligand inhibitor. We chose a saturated aliphatic
compound with a leaving group at one end, to form an ether with the phenol at the
“aminooxazole end”, and a carboxylic acid at the other end to forge an amide with the Nterminus of the moiramide fragment. We arbitrarily started with a 15-carbon linker since
juniperic acid (compound 26, Scheme 2.4) is commercially available. We later also
synthesized a 7-carbon linker (compound 29, Scheme 2.4) to more accurately mimic the
fatty acid component of moiramide B.

This design strategy generates dual-ligand

inhibitors that incorporate the necessary pharmacophores for targeting both biotin
carboxylase and carboxyltransferase while covalently attaching them using stable,
saturated hydrocarbon linkers of various lengths (Figure 2.3).

Figure 2.3.
Dual-ligand inhibitors containing aminooxazole and moiramide
pharmacophores with saturated hydrocarbon linkers with 15 carbons (5) and 7 carbons
(6).
2.2.2 Chemistry
We generated the requisite unsymmetrical dibenzylamine via reductive amination
of benzaldehyde with p-aminophenol to give compound 10 (Scheme 2.2).21 Coupling of
aminooxazole carboxylate 12 with secondary amine 10 afforded compound 13 (Scheme
2.2), the “aminooxazole” component of the dual-ligand inhibitor, with a handle for
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attachment to other species.10 However, compound 2 was also synthesized and used in
biological studies as the “aminooxazole only” representative in order to eliminate any
side reactions that might have been encountered with the phenol functionality of 13.

Scheme 2.2. Synthesis of aminooxazole 2 and aminooxazole 13 with para-hydroxyl
group. Reagents and conditions: (i) triethylamine, dry methanol, 3Å molecular sieves,
65%; (ii) NaBH4, dry methanol, 0 °C to rt, 84%; (iii) 1. 2M NaOH, 60 °C; 2. HCl, 98%;
(iv) HATU, triethylamine, dry DMF, 31-35%.
Andrimid (3) and moiramide B (4) have been synthesized previously, although
most reports are in communication format without experimental details.13,

22-24

These

accounts all alluded to the fragility of the -ketoamide functionality; the pKa for enolate
formation of andrimid is 6.8.25 We prepared (4S)-methyl-succinic anhydride 15 (Scheme
2.3) according to Midgley and Thomas26 and converted this to the benzyl succinimide
17.27 Indeed, Pohlmann et al. had prepared a number of N-alkylated derivatives of
moiramide for SAR studies but they did not prepare the benzyl derivative and it was not
clear why they and others used benzyloxy protection for the succinimide nitrogen, which
requires two steps for removal. We expected to cleave the benzylamine in a single
hydrogenolytic step.
With 17 in hand, we faced the challenging acylation of the kinetic enolate of 17
with an acyl cation equivalent derived from N-tert-butoxycarbonyl-L-valine (Boc-Val-
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OH). The discussion of Davies and Dixon informed us that the enolate was unstable and
must be generated in the presence of an appropriate electrophile.24 While they employed
an N-carboxyanhydride, others invoked an acyl imidazole.13,

23

We found the acyl

imidazole was more convenient to generate and more stable than the Ncarboxyanhydride. The acyl imidazole generated from Boc-Val-OH was added to a
solution of succinimide 17. The solution was added slowly to a solution of LiHMDS in
THF at -78 °C. While TLC analysis of the reaction looked promising, poor yields of 18
were obtained by flash chromatography. Two-dimensional TLC confirmed that 18 was
unstable to silica gel and was thus isolated by reversed-phase HPLC in low yield.
Furthermore, the product was not particularly stable and standard hydrogenolysis
procedures for removing the benzyl protecting group were unsuccessful.

Scheme 2.3. Synthesis of moiramide 25 with free amine and moiramide B (4). Reagents
and conditions: (i) AcCl, 60 °C, 97%; (ii) 1. Compound 16, THF, Δ; 2. Ac2O, Δ, 83%;
(iii) Compound 19, CDI, triethylamine, CH2Cl2, 89%; (iv) 1. N-Boc-L-valine, CDI, dry
THF; 2. LiHMDS, -78 °C, dry THF, 42%; (v) 1. H2, 5% Pd/C (20% w/w), dry methanol;
2. 2-bromoacetophenone, triethylamine, CH3CN, 64%; (vi) TFA:CH2Cl2, 0 °C, 89-98%;
(vii) (S)-N-Boc-3-amino-3-phenylpropanoic acid, HATU, iPr2NEt, dry DMF, 0 °C to rt,
45%; (viii) Sorbic acid, TBTU, iPr2NEt, dry DMF, 32%.
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The N-benzyl group was replaced with the N-benzyloxy protecting group,
ultimately leading to compound 21 (Scheme 2.3) that was remarkably stable to silica gel.
An earlier paper by Robin et al., outlining a synthesis of thalidomide, also utilized
benzyloxy protection of the glutarimide ring, where the benzyl group had been
problematic.28 They suggested that resonance donation of electron density from the
oxygen reduces the electrophilicity of the C=O groups and the acidity of the neighboring
alpha protons. The acylation of 20 and purification of 21 was now realized in a better
yield of 42% and the product was stable and generated an equilibrium mixture of
predominantly the trans diastereomer and <10% of the diastereomer with cis-relative
stereochemistry on the succinimide ring that arises via tautomerization to the enol form,
evident in <6%. Earlier reports did not include NMR spectra as Supporting Information,
although Davies and Dixon reported an 87:9:4 (trans:enol:cis) mixture for compound 21.
The benzylic C-O bond in 21 was cleaved by hydrogenolysis to afford the hydroxylamine
that was treated with 2-bromoacetophenone to generate the phenacyl ester in situ which
ultimately led to succinimide 22.24 The deprotected succinimide 22 existed as an 82:4:14
(trans:enol:cis) mixture; Davies and Dixon did not report a ratio of isomers for this
compound. Removal of the Boc group at the N-terminus of compound 22 and elongation
with commercially available Boc--Phe-OH gave compound 24. The addition of the
Boc-β-Phe moiety resulted in a single diastereomer, suggesting a stronger
thermodynamic preference for the trans isomer with the larger acyl side chain.
Compound 24 in turn underwent Boc deprotection to afford the free amine 25 that was
coupled to sorbic acid to generate the natural product, moiramide B (compound 4,
Scheme 2.3).
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Preparation of the 15 carbon linker followed a procedure that Overman and
coworkers had previously reported for the conversion of juniperic acid 26 to allyl ester 27
(Scheme 2.4).29 The primary alcohol was converted to an alkyl iodide (28) by analogy to
a procedure of Jobron et al.30 We also prepared a significantly shorter linker, 31, from 8hydroxyoctanoic acid (29) as shown in Scheme 2.4.

Scheme 2.4. Synthesis of modified saturated hydrocarbon linkers 28 and 31. Reagents
and conditions:
(i) allyl alcohol, H2SO4, Δ, 59-61%; (ii) polymer-bound
triphenylphosphine, I2, imidazole, dry CH2Cl2, 78-83%.
The convergent assembly of the three fragments to generate the dual-ligand
inhibitors is depicted in Scheme 2.5. The phenol of compound 13 was activated as the
corresponding cesium salt using CsOH. This accentuated nucleophile then participated in
an SN2 reaction with the iodide of compounds 28 and 31 to generate an ether linkage viz.
aminooxazole-linker derivatives 32 and 33, respectively. The allyl protecting group of
each derivative was removed by hydrolysis to generate the free carboxylic acids 34 and
35, by a procedure analogous to Zhang et al.31 The acids were each coupled to the amine
in compound 25 using standard coupling reagents to generate the dual-ligands 5 and 6
with optimized conditions for each compound (Scheme 2.5).13
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Scheme 2.5. Synthesis of dual-ligand inhibitors 5 and 6. Reagents and conditions: (i) 1.
CsOH, dry DMF; 2. Compounds 28 or 31, dry THF, Δ, 20-21%; (ii) 2M NaOH,
MeOH:THF, 71-89%; (iii) Compound 34, HOBt, EDC, triethylamine, dry DMF, 19%;
(iv) Compound 35, HATU, iPr2EtN, dry DMF, 0 °C to rt, 17%.

2.2.3 Inhibition of Acetyl-CoA Carboxylase by the Dual-Ligands
The targets of the antibacterial agents aminooxazole 2 and moiramide B (4) are
biotin carboxylase and carboxyltransferase, respectively. The question now is: how
would a molecule that incorporates the features of both aminooxazole 2 and moiramide B
(4) inhibit the multiprotein complex comprising all three components of acetyl-CoA
carboxylase (ACC)? Recent studies have shown that the three components of ACC:
biotin carboxylase, BCCP and carboxyltransferase, form a multiprotein complex both in
vitro and in vivo.20 In order to compare the dual-ligand inhibitors to the two parent
compounds, the inhibition of ACC by aminooxazole 2 and moiramide B (4) was also
studied because the original characterization of these inhibitors utilized only the isolated
subunits of biotin carboxylase or carboxyltransferase, not the ACC complex.
The inhibition of ACC by aminooxazole 2 was determined by varying ATP at
increasing fixed concentrations of inhibitor, where acetyl-CoA was held constant at a
subsaturating level. Aminooxazole 2 exhibited noncompetitive inhibition versus ATP
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and this pattern was unexpected based on the competitive inhibition versus ATP that was
observed with the isolated subunit of biotin carboxylase (Figure 2.4). However, the Kis of
0.8 ± 0.2 M for isolated biotin carboxylase was close to the Kis value observed for ACC.
Aminooxazole 2 exhibited a Kis of 0.4 ± 0.1 M and a Kii of 0.9 ± 0.2 M, Figure 2.5,
(A).

Figure 2.4. Inhibition of biotin carboxylase by 2-amino-N,N-dibenzyloxazole-5carboxamide (2) at: 0 M (●), 0.3 M (■), and 0.7 M (▲). The substrate ATP was
varied while holding the other substrates, HCO3- and biotin, constant at 15 mM and 48
mM, respectively. The points represent the observed velocities and the lines represent
the best fit of the data to Eq. 1.
The reason for the noncompetitive pattern in ACC is not clear at this time and
awaits the determination of the three-dimensional structure of ACC bound to
aminooxazole 2. Nonetheless, the noncompetitive inhibition pattern observed for ACC
has implications for targeting the biotin carboxylase subunit of the enzyme for
pharmaceutical purposes. Namely, the noncompetitive inhibition pattern means that
inhibitor binding is not precluded by saturating levels of ATP. Given that the Km for
ATP in ACC is about 1-2 M20 and the intracellular level of ATP in log phase E. coli is 9
mM32, ACC is very likely saturated with the substrate ATP in vivo. Thus, at least for the
biotin carboxylase inhibitor, aminooxazole 2, saturation with ATP will not be
problematic. These results show that it is imperative that any potential antibacterial
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agents targeting either the biotin carboxylase or carboxyltransferase subunits of ACC
must be characterized with ACC in toto and not just the isolated subunits because the
multiprotein complex is the active form of the enzyme in vivo.
Moiramide B 4

Aminooxazole 2

Dual-Ligand 5

Dual-Ligand 5

Dual-Ligand 6

Dual-Ligand 6

Figure 2.5. Inhibition of acetyl-CoA carboxylase. (A) Inhibition by 2-amino-N,Ndibenzyloxazole-5-carboxamide (2) at: 0 M (●), 0.3 M (■), and 0.7 M (▲). (B)
Inhibition by dual-ligand inhibitor 5 at: 0 nM (●), 6 nM (■), and 10 nM (▲). (C)
Inhibition by dual-ligand inhibitor 6 at: 0 nM (●), 6 nM (■), and 10 nM (▲). For all
three assays, the substrate ATP was varied while holding the other substrates, HCO3- and
acetyl-CoA, constant at 15 mM and 200 M, respectively. The points represent the
observed velocities and the lines represent the best fit of the data to Eq. 2. (D) Inhibition
by moiramide B (4) at: 0 nM (●), 3 nM (■), and 6 nM (▲). (E) Inhibition by dual-ligand
inhibitor 5 at: 0 nM (●), 6 nM (■), and 10 nM (▲). (F) Inhibition by dual-ligand
inhibitor 6 at: 0 nM (●), 6 nM (■), and 10 nM (▲). For all three assays, the substrate
acetyl-CoA was varied while holding the other substrates, HCO3- and ATP, constant at 15
mM and 5 M, respectively. The points represent the observed velocities and the lines
represent the best fit of the data to Eq. 1.
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The inhibition of ACC by moiramide B was determined by varying acetyl-CoA at
increasing fixed concentrations of inhibitor, while ATP was held constant at a
subsaturating level. Moiramide B exhibited competitive inhibition versus acetyl-CoA
with a Kis of 7.9 ± 1.1 nM, Figure 2.5, (D). These results are similar to the competitive
inhibition pattern of moiramide B (4) versus malonyl-CoA and Kis value of 5 nM for the
isolated subunit of carboxyltransferase.12
For the dual-ligands, inhibition patterns using biochemical assays were
determined versus both ATP and acetyl-CoA. The inhibition of ACC by dual-ligand 5
(15C linker) versus ATP at increasing fixed concentrations of inhibitor, with acetyl-CoA
held constant at a subsaturating level, exhibited noncompetitive inhibition with a Kis of
28.7 ± 12.9 nM and a Kii of 33.7 ± 7.2 nM, Figure 2.5, (B). The inhibition of ACC by
dual-ligand 5 versus acetyl-CoA at increasing fixed concentrations of inhibitor, with ATP
held constant at a subsaturating level, exhibited competitive inhibition with a Kis of 5.2 ±
0.7 nM, Figure 2.5, (E).
The inhibition of ACC by dual-ligand 6 (7C linker) versus ATP at increasing
fixed concentrations of inhibitor, with acetyl-CoA held constant at a subsaturating level,
exhibited noncompetitive inhibition with a Kis of 16.9 ± 6.8 nM and a Kii of 9.6 ± 1.0 nM,
Figure 2.5, (C). The inhibition of ACC by dual-ligand 6 versus acetyl-CoA at increasing
fixed concentrations of inhibitor, with ATP held constant at a subsaturating level,
exhibited competitive inhibition with a Kis of 5.5 ± 0.6 nM, Figure 2.5, (F).
The noncompetitive inhibition pattern versus ATP and the competitive pattern
versus acetyl-CoA observed for both dual-ligands, 5 and 6, could be due to the linker not
being long enough to allow both parts of the dual-ligands to bind to the enzyme
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simultaneously. As a consequence, the dual-ligands, 5 and 6, only bind in the moiramide
B binding site, by virtue of its higher affinity, compared to aminooxazole 2. While this is
a plausible explanation for the noncompetitive inhibition pattern versus ATP, it is
inconsistent with the fact that the “parent” compound, aminooxazole 2, also exhibited
noncompetitive inhibition versus ATP in ACC. Thus, the inhibition patterns for the two
dual-ligands, 5 and 6, are perfectly consistent with the inhibition patterns observed for the
two “parent” compounds, aminooxazole 2 and moiramide B (4). The molecular basis for
the inhibition patterns will ultimately be revealed by the determination of the threedimensional structure of ACC bound to either of the dual-ligands.
2.2.4 Antibacterial Activity of Dual-Ligands
Figure 2.6 lists the minimum inhibitory concentration (MIC) values for the
“parent” compounds, aminooxazole 2 and moiramide B (4), as well as dual-ligands 5 and
6 against different bacterial strains. Aminooxazole 2 exhibited antibacterial activity
against efflux-pump deficient E. coli and in fact, registered the same MIC value of 16
g/mL as reported by Mochalkin et al.10 Also consistent with the findings of Mochalkin
et al., aminooxazole 2 was not active against any Gram-positive bacteria.10 Moreover,
aminooxazole 2 was effective against an E. coli tolC derivative that was selected for
spontaneous resistance to moiramide B (4) suggesting that dual-ligands such as 6 would
retain activity against strains bearing pre-existing moiramide-resistance.
Moiramide B (4) exhibited antibacterial activity against all strains tested except
the wild-type strains of P. aeruginosa and E. coli. The lack of activity against these
strains can be attributed to efflux-based intrinsic resistance, since efflux-pump-deficient
strains of these organisms were susceptible to moiramide B (Figure 2.6). Moiramide B
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also exhibited activity against spontaneous moiramide-resistant isolates of both E. coli
tolC and S. aureus, with an observed 8-fold decrease in potency in each case. The
elevated MICs against moiramide B suggest that some stable drug resistance was
observed, most likely through a target-based spontaneous mutation. The results reported
herein for moiramide B are consistent with previously reported antibacterial analyses.1213, 33

Strain (genotype)a
P. aeruginosa (wild-type)
P. aeruginosa (ΔRND)c
E. coli (wild-type)
E. coli (lpxC101 )
E. coli (tolC )
E. coli (tolC, moir-R)d
E. coli (lpxC101, tolC )d
S. aureus (wild-type)
S. aureus (moir-R)
S. aureus (norA up)
S. epidermidis (wild-type)
E. faecalis (wild-type)

Rifampin
31
31
31
0.06
8
ND
0.5
≤0.03
ND
≤0.03
≤0.03
0.5

MICb (μg/mL)
Gentamicin Chloramphenicol Kanamycin
2
>64
128
0.5
2
64
0.1
8
2
0.12
4
1
0.24
1
2
ND
ND
0.5
≤0.03
1
0.5
0.5
8
4
ND
ND
2
0.5
8
4
8
8
>128
8
8
31

2
>64
>64
>64
>64
16
8
16
>64
>64
>64
>64
>64

4
>64
8
>64
4
0.5
4
0.5
1
8
4
0.24
8

5
>64
>64
>64
>64
>64
ND
>64
>64
ND
>64
>64
>64

6
>64
>64
>64
>64
8
16
4
4
>64
4
1
4

The following designate targeted deletion mutants of efflux pumps or subunits of efflux pumps: mexAB,
mexCD, mexXY, mexHI, opmH, tolC. The lpxC101 allele enhances permeability of the E. coli outer
membrane. The norAup genotype results from a spontaneous mutation in S. aureus resulting in a gain of
function of the norA efflux pump. The designation moir-R indicates a spontaneous moiramide resistance
selected with moiramide B containing agar at 4-8x MIC. Wild-type P. aeruginosa is PA01; Wild-type E.
coli is D21; Wild-type S. aureus is ATCC #29213; Wild-type S. epidermidis is ATCC #35984; Wild-type
E. faecalis is ATCC #29212.
b
Determined by the broth microdilution method.
c
(ΔRND) = mutation of mexAB, mexCD, mexXY, mexHI, opmH.
d
These strains show a slight growth defect on agar medium.
ND = Not determined
a

Figure 2.6. Antibacterial activities of synthesized compounds against strains of bacteria.
Of the dual-ligands tested, compound 6 bearing the shorter 7C linker was found to
exhibit the best overall antibacterial activity in MIC assays (Figure 2.6). Antibacterial
activity was observed against an efflux compromised E. coli strain lacking the tolC outer
membrane channel and wild-type S. aureus. In fact, dual-ligand 6 was effective against
all of the Gram-positive strains investigated. Of particular note and, in contrast to
moiramide B (4), dual-ligand 6 no longer seems to be subject to norA-based efflux in S.
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aureus as the MIC remain unchanged at 4 g/mL when tested against wild-type S. aureus
and an otherwise isogenic strain bearing a gain-of-function mutation34 effecting norAbased efflux activity. Dual-ligand 6 was also still effective against moiramide-resistant
E. coli tolC but virtually ineffective against moiramide-resistant S. aureus. This result is
wholly expected given that the secondary pharmacophore (the aminooxazole derivative)
is not effective against Gram-positive bacteria due to a threonine residue at position 437
of biotin carboxylase (which is an isoleucine in Gram-negative bacteria) causing a loss in
necessary hydrophobic contacts between the inhibitor and the binding pocket.9 Lastly,
while the antibacterial activity of dual-ligand 6 is similar to moiramide B in most strains
there was an increase in potency for dual-ligand 6 with an MIC of 4 g/mL against E.
faecalis, whereas moiramide B (4) showed an MIC of 8 g/mL. The absence of any
apparent antibacterial activity of dual-ligand 5 is unexpected as dual-ligand 5 did, in fact
inhibit the holoenzyme ACC. We speculated that dual-ligand 5 might be impaired in its
ability to diffuse through the bacterial membrane due to the presence of the longer,
hydrophobic linker.
2.2.5 Effect of PMBN on the Antibacterial Activity of Dual-Ligand 5
Polymyxin B nonapeptide (PMBN) is a cationic cyclic peptide that is a nonbactericidal version of the antibiotic polymyxin B (PMB). PMBN binds to the bacterial
lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria which
leads to increased susceptibility to the passage of hydrophobic antibiotics.35-36 Therefore,
the effect of PMBN on the antibacterial activity of dual-ligand 5 was examined to
determine whether or not an inability to diffuse across the bacterial membrane was the
reason for the lack of observed antibacterial activity.
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The antibacterial activity of dual-ligand 5 when co-incubated in E. coli with
PMBN is shown in Figure 2.7. As expected, there was no antibacterial activity observed
for dual-ligand 5 when inoculated in E. coli without PMBN. However, with increasing
amounts of PMBN, dual-ligand 5 did inhibit bacterial growth (Figure 2.7).

Figure 2.7. Effect of polymyxin B nonapeptide (PMBN) on the antibacterial activity of
dual-ligand 5. Increasing amounts of PMBN (0, 0.5, 1, 5, 10 g/mL) were added to
different fixed concentrations of dual-ligand 5 (1, 10, 50, 100 M) and the solutions were
inoculated with E. coli and incubated at 37 °C. After a 4 hour incubation, the absorbance
at 600 nm was measured.
Concentrations of 10, 50, and 100 M of dual-ligand 5 inhibited growth of E. coli
when inoculated with at least 5 g/mL of PMBN. There was no significant inhibition of
growth with only 1 M of dual-ligand 5, even with the addition of PMBN. Control
experiments showed no growth inhibition when E. coli was inoculated with only PMBN
at the highest concentration (10 g/mL) used in the assay. These results strongly suggest
that the lack of antibacterial activity of dual-ligand 5, even at high concentrations, was
due to an inability to diffuse across the bacterial membrane. Thus, the antibacterial
activity of dual-ligand 5 in the presence of PMBN can be attributed to the ability of dualligand 5 to enter the cell and inhibit ACC. This result implies synergy between PMBN
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and dual-ligand 5 which can be beneficial when developing combination therapies
targeting Gram-negative pathogens.37-38
2.2.6 Single-step Resistance Studies
One of the potential advantages of a dual-ligand antibacterial agent versus a
molecule directed against a single target is a lower likelihood of developing resistance.
To this end, the spontaneous resistance frequencies were determined for rifampin,
aminooxazole 2, moiramide B (4), and dual-ligand 6 against the E. coli tolC mutant
(Figure 2.8). Compared to the control rifampin, aminooxazole 2 had a lower frequency
of resistance and in general, was found to be a poor inhibitor in these assays. In contrast,
the mutant prevention concentrations (MPC) for moiramide B (4) and dual-ligand 6 were
16 mg/L and 64 mg/L, respectively. This allowed for the calculation of mutant selection
windows (MSWs) for these compounds where the MSW is the MPC/MIC ratio, with an
ideal drug having an MSW of 1.39 The MSW values for moiramide B and dual-ligand 6
were 32 and 8, respectively. Thus, dual-ligand 6 has a narrower MSW suggesting it has
more restriction for selection of resistance. Lastly, when dosed at 8x the MIC value,
moiramide B and dual-ligand 6 both exhibited an observed resistance frequency of <2.5 x
10-10. This number was too low to determine any significant difference between the two
compounds. Therefore, it could not be assessed if dual-ligand 6 has a lower frequency of
resistance when compared to the two “parent” compounds. Nonetheless, when compared
to rifampin and aminooxazole 2, dual-ligand 6 clearly has a much lower potential for
spontaneous resistance development.
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Compound

MICa
(mg/L)

Rifampin

8

MPCb
(mg/L)
>64

2

16

4
6

MSWc

Resistance
d

Frequency
-9

>8

7 x 10

>128

>8

1.75 x 10

0.5

16

32

<2.5 x 10

8

64

8

<2.5 x 10-10

-9

-10

a

Determined from broth microdilution in MHII broth.
MPC is the drug dose at which resistant mutants (using 4x10 9 CFU) were no longer obtained.
c
MSW is the ratio of the MPC to the MIC.
d
Resistance frequency is the number of resistant colonies observed over the total number of CFU plated at
8x MIC
b

Figure 2.8. Results of single-step resistance selection studies with the E. coli tolC strain.
2.3

CONCLUSIONS
The studies in this report provide “proof-of-concept” that a dual-ligand inhibitor

of the multifunctional enzyme ACC can act as an antibacterial agent. First, the synthesis
of the dual-ligand inhibitor led to significant improvements in the synthetic protocol for
the moiramide B (4) moiety. Second, incorporating two known inhibitors for the two
enzymes comprising ACC, biotin carboxylase and carboxyltransferase, into a single
chemical entity yielded a potent (nM inhibition constant) inhibitor of the enzyme. An
unexpected but potentially far-reaching finding was that the aminooxazole 2, exhibited
noncompetitive inhibition of biotin carboxylase with respect to ATP in ACC, but
competitive inhibition in the isolated biotin carboxylase subunit. This indicates that
inhibitors of biotin carboxylase discovered using the isolated subunit may react
differently with ACC. Third, the finding that dual-ligand 5 had little to no antibacterial
activity, while dual-ligand 6 exhibited antibacterial activity against Gram-negative and
Gram-positive organisms indicates that the choice of the linking component is critical for
determining whether dual-ligand inhibitors which show activity in biochemical assays
will also show antibacterial activity. Based on our results, we speculate that the more
hydrophobic the linker is, the less likely it is to diffuse across the bacterial membrane.
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While the pharmacophore involving aminooxazole 2 was not as potent as the moiramide
B (4) moiety, it did retain appreciable antibacterial activity in vitro. Importantly, many
novel aminooxazole derivatives were recently reported as part of a recent virtual
screening study40 which identified several million aminooxazole derivatives that could
potentially be linked to moiramide B (4) to generate a wide array of dual-ligand hybrids.
These new dual-ligands could, in turn, be screened for potent broad spectrum
antibacterial activity using the tools and techniques described herein. Future studies will
seek to test this proposal directly and will undoubtedly provide new and important
information about the activity of dual-ligand inhibitors against this novel target.
2.4

EXPERIMENTAL SECTION

2.4.1 Materials and Methods
All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, Acros,
NovaBiochem, Matrix, Combi-Blocks or Fluka and used without further purification.
Diisopropylethylamine and triethylamine were dried and distilled from CaH2 and stored
over KOH pellets. Dry methanol was distilled from Mg turnings and stored over 3Å
molecular sieves. All reactions were performed under a dry nitrogen atmosphere unless
otherwise noted. Flash chromatography was performed using 230-400 mesh silica gel
(40-63 m) from Sigma-Aldrich. Thin layer chromatography (TLC) was performed on
aluminum-backed 60 F254 silica plates from EMD Chemicals, Inc. Optical rotations were
recorded on a Jasco P-2000 digital polarimeter. Circular dichroism (CD) spectrum was
recorded on a Jasco J-815 Circular Dichroism spectrometer.

1

H and

13

C NMR spectra

were recorded at room temperature on a Bruker AV-400 or AV-500 spectrometer. All
NMR experiments were performed in deuterated solvents and the chemical shifts are
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reported in standard δ notation as parts per million, using tetramethylsilane (TMS),
CDCl3, DMSO-d6, or acetone-d6 as an internal standard for 1H and
coupling constants (J) reported in Hertz (Hz).

13

C NMR, with

High resolution mass spectrometry

(HRMS) was carried out using an Agilent 6210 electrospray ionization-time-of-flight
(ESI-TOF) mass spectrometer.
Synthesis of (E)-4-[(benzylideneamino)methyl]phenol (9). Benzaldehyde 7 (413
L, 431 mg, 4.06 mmol, 1.00 equiv.) was added to a suspension of 3Å molecular sieves
(150 mg/100 mg amine), triethylamine (736 L, 534 mg, 5.28 mmol, 1.30 equiv.), and 4hydroxybenzylamine 8 (500 mg, 4.06 mmol, 1.00 equiv.) in dry methanol (1.0 mL/100
mg amine) at rt under N2. The mixture was stirred at rt for 18 h. The molecular sieves
were removed by filtration through a pad of Celite®, washing well with dry methanol
and the filtrate was concentrated in vacuo to give 9 as a light brown solid (556 mg,
65%).3 1H NMR (DMSO-d6, 400 MHz) δ 4.64 (s, 2H), 6.72 (d, J = 8.4 Hz, 2H), 7.11 (d,
J = 8.4 Hz, 2H), 7.41-7.49 (m, 3H), 7.70-7.81 (m, 2H), 8.44 (s, 1H), 9.33 (br s, 1H); 13C
NMR (DMSO-d6, 100 MHz) δ 64.1, 115.6, 128.4, 129.1, 129.6, 130.1, 131.1, 136.6,
156.7, 161.5.

HRMS (ESI-TOF) calcd for C14H14NO (M+H)+: 212.1070, obsd:

212.1070.
Synthesis of 4-[(benzylamino)methyl]phenol (10). Sodium borohydride (154 mg,
4.06 mmol, 1.80 equiv.) was added in portions to a solution of 9 (556 mg, 2.63 mmol,
1.00 equiv.) in dry methanol (5 mL) at 0 °C. The mixture was stirred for 18 h under N 2
while allowing to warm to rt.

The mixture was concentrated and then partitioned

between CH2Cl2 (10 mL) and water (10 mL). The aqueous layer was further extracted
3

No Rf was obtained for imine compound as product hydrolyzed on silica.
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with CH2Cl2 (2 x 10 mL). The combined organic layers were washed with brine, dried
over MgSO4, filtered, and concentrated to give 10 as a light brown solid (470 mg, 84%).
Rf 0.27 (3:2 CH2Cl2:EtOAc).

1

H NMR (acetone-d6, 400 MHz) δ 3.69 (s, 2H), 3.77 (s,

2H), 5.55 (s, 1H), 6.80 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4, 2H), 7.23 (d, J = 7.4 Hz, 1H),
7.30 (t, J = 7.4 Hz, 2H), 7.37 (d, J = 7.4 Hz, 2H);

13

C NMR (acetone-d6, 100 MHz) δ

52.2, 52.5, 115.3, 126.7, 128.2, 128.3, 129.5, 130.9, 140.7, 156.7. HRMS (ESI-TOF)
calcd for C14H16NO (M+H)+: 214.1226, obsd: 214.1225.
Synthesis of 2-aminooxazole-5-carboxylic acid (12).10 Ethyl 2-aminooxazole-5carboxylate 11 (2.00 g, 12.8 mmol) was added to 2M aqueous NaOH (50 mL) and stirred
at rt for 2 h. The mixture was heated to 60 °C and stirred for an additional 2 h.
Concentrated hydrochloric acid was added dropwise to the reaction mixture until it
became acidic by pH paper (pH ~3-4) and a colorless precipitate began to form. The
mixture was cooled in the freezer for 1 h. The resulting solid was collected by filtration
and washed with acetonitrile to give 12 as a colorless solid (1.60 g, 98%). Rf 0.24 (6:4:1
CHCl3:MeOH:H2O).

1

H NMR (DMSO-d6, 400 MHz) δ 7.38 (s, 2H), 7.44 (s, 1H);

13

C

NMR (DMSO-d6, 100 MHz) δ 136.0, 137.1, 159.1, 164.1. HRMS (ESI-TOF) calcd for
C4H5N2O3 (M+H)+: 129.0295, obsd: 129.0296.
General procedure for the synthesis of aminooxazole derivatives (2 and 13).
Amine (1.00 equiv.) was added to a solution of 12 (1.00 equiv.) and triethylamine (2.00
equiv.) in dry DMF (10 mL). HATU (1.00 equiv.) was added to the solution and the
mixture stirred for 20 h under N2. The mixture was partitioned between EtOAc (25 mL)
and water (20 mL). The aqueous layer was further extracted with EtOAc (2 x 20 mL).
The combined organic layers were washed with sat’d aq. NaHCO3 (15 mL), brine (15
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mL), dried over MgSO4, filtered, and concentrated. The resulting residue was dissolved
in EtOAc (20 mL) and placed in a freezer overnight. The resulting precipitate was
collected by filtration, washed with EtOAc, and dried.
Synthesis of 2-amino-N,N-dibenzyloxazole-5-carboxamide (2).10 Starting from
dibenzylamine (249 L, 256 mg, 1.30 mmol), carboxylic acid 12 (166 mg, 1.30 mmol),
triethylamine (362 L, 262 mg, 2.59 mmol) and HATU (493 mg, 1.30 mmol), the general
procedure gave 2 as a colorless solid (124 mg, 31%). Rf 0.16 (3:2 CH2Cl2:EtOAc). 1H
NMR (DMSO-d6, 400 MHz) δ 4.65 (br s, 4H), 7.06-7.41 (m, 13H); 13C NMR (DMSO-d6,
100 MHz) δ 49.9, 52.5, 127.7, 128.5, 128.6, 129.1, 134.9, 137.4, 137.7, 159.0, 163.1.
HRMS (ESI-TOF) calcd for C18H18N3O2 (M+H)+: 308.1394, obsd: 308.1399.
Synthesis of 2-amino-N-benzyl-N-(4-hydroxybenzyl)oxazole-5-carboxamide (13).
Starting from amine 10 (1.20 g, 5.64 mmol), carboxylic acid 12 (721 mg, 5.64 mmol),
triethylamine (1.57 mL, 1.14 g, 11.3 mmol), and HATU (2.14 g, 5.64 mmol), the general
procedure gave 13 as a colorless solid (633 mg, 35%). Rf 0.57 (9:1 CH2Cl2:MeOH). 1H
NMR (DMSO-d6, 400 MHz) δ 4.51 (s, 2H), 4.59 (s, 2H), 6.73 (d, J = 8.1 Hz, 2H), 7.42
(m, 10H), 9.40 (s, 1H);

13

C NMR (DMSO-d6, 100 MHz) δ 49.3, 115.8, 127.6, 129.1,

134.7, 137.5, 137.8, 157.1, 158.8, 163.1.

HRMS (ESI-TOF) calcd for C18H18N3O3

(M+H)+: 324.1343, obsd: 324.1371.
Synthesis of (4S)-methyl-succinic anhydride (15). Acetyl chloride (4.53 mL, 4.75
g, 60.6 mmol, 4.00 equiv.) was added to (4S)-methylsuccinic acid 14 (2.00 g, 15.1 mmol,
1.00 equiv.) and heated gently at reflux for 6 h. Excess acetyl chloride and acetic acid
were removed in vacuo to give 15 as a colorless solid (1.70 g, 97%).24 Rf 0.76 (9:1
CH2Cl2:MeOH). []D24 -33.0 (c 1.77, CHCl3) [Lit.24 []D24 -36.3 (c 1.77, CHCl3)].
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1

H

NMR (CDCl3, 400 MHz) δ 1.30 (d, J = 7.2 Hz, 3H), 2.45-2.56 (m, 1H), 2.99-3.17 (m,
2H);

13

C NMR (CDCl3, 100 MHz) δ 16.1, 35.6, 36.0, 169.9, 174.3. HRMS (ESI, -ve,

TOF) calcd for C5H5O3 (M-H)+: 113.0244, obsd: 113.0244.
Synthesis of (4S)-methyl-N-O-benzylsuccinimide (20).13

Triethylamine (1.08

mL, 787 mg, 7.78 mmol, 1.05 equiv.) was added to a solution of 15 (845 mg, 7.41 mmol,
1.00 equiv.) in CH2Cl2 (5 mL) at 0 °C followed by addition of O-benzylhydroxylamine
hydrochloride 19 (1.24 g, 7.78 mmol, 1.05 equiv.). The mixture was warmed to rt
overnight under N2 and then 1,1’-carbonyldiimidazole (1.32 g, 8.15 mmol, 1.10 equiv.)
was added in portions. The mixture was stirred at rt for 1.5 h and then heated at reflux
for 30 min. The mixture was cooled to rt and the organic layer was washed with 10%
hydrochloric acid (2 x 10 mL). The organic layer was washed with brine (10 mL), dried
over MgSO4, filtered, and concentrated to give 20 as a colorless solid (1.44 g, 89%). Rf
0.64 (4:1 EtOAc:Hex). []D23 -2.0 (c 0.72, CHCl3) [Lit.24 []D24 –4.9 (c 0.72, CHCl3)].
1

H NMR (CDCl3, 400 MHz) δ 1.25 (d, J = 7.2 Hz, 3H), 2.20 (dd, J = 17.5, 3.6 Hz, 1H),

2.67-2.80 (m, 1H), 2.82 (dd, J = 17.6, 8.9 Hz, 1H), 5.13 (s, 2H), 7.28-7.40 (m, 3H), 7.437.56 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 16.7, 32.0, 33.7, 78.5, 128.5, 129.5, 130.1,
133.2, 170.6, 174.7. HRMS (ESI-TOF) calcd for C12H13NaNO3 (M+Na)+: 242.0788,
obsd: 242.0804.
Synthesis of (3S)-Boc-L-valine-(4S)-methyl-N-O-benzylsuccinimide (21).13, 24 A
solution of Boc-L-valine (992 mg, 4.56 mmol, 1.00 equiv.) and 1,1’-carbonyldiimidazole
(814 mg, 5.02 mmol, 1.10 equiv.) in dry THF (4 mL) was stirred at rt for 2 h under N2. A
solution of 20 (1.00 g, 4.56 mmol, 1.00 equiv.) in dry THF (8 mL) was added to the
acylimidazole mixture at rt. This combined solution was then added dropwise over 45
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min to a stirring solution of lithium hexamethyldisilazide (9.13 mL, 1.00 M, 9.13 mmol,
2.00 equiv.) in dry THF (6 mL) under N2 at -78 °C. After the addition was complete, the
mixture was stirred at -78 °C for an additional 15 min and then quenched with sat’d aq.
ammonium chloride (5 mL). The reaction mixture was allowed to warm to rt and then
partitioned between Et2O (20 mL) and water (20 mL). The organic phase was washed
with brine (20 mL), dried over MgSO4, filtered, and concentrated. The resulting residue
was purified by flash chromatography on silica gel eluting with 3:1 Hex:EtOAc to give
21 as a colorless solid (800 mg, 42%). Rf 0.45 (2:1 Hex:EtOAc). []D23 -30.1 (c 0.70,
CHCl3) [Lit.24 []D23 -33.9 (c 0.70, CHCl3)]. 1H NMR (CDCl3, 400 MHz) δ 0.78 (d, J =
6.7 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H), 1.23 (d, J = 7.4 Hz, 3H), 1.46 (s, 9H), 2.24-2.41
(m, 1H), 3.14-3.30 (m, 1H), 3.71 (d, J = 4.0 Hz, 1H), 4.44 (dd, J = 8.8, 4.8 Hz, 1H), 5.09
(s, 2H), 5.60 (d, J = 8.6 Hz, 1H), 7.30-7.39 (m, 3H), 7.40-7.46 (m, 2H);

13

C NMR

(CDCl3, 100 MHz) δ 15.6, 17.3, 19.6, 28.3, 29.6, 34.5, 55.0, 65.1, 78.7, 80.2, 128.6,
129.6, 130.2, 132.9, 156.0, 166.6, 173.1, 201.9.

HRMS (ESI-TOF) calcd for

C22H30NaN2O6 (M+Na)+: 441.1996, obsd: 441.1994.
Synthesis of (3S)-Boc-L-valine-(4S)-methyl-succinimide (22).24

A catalytic

amount of 5% Pd/C (127 mg, 20% w/w) was added to a solution of 21 (637 mg, 1.52
mmol, 1.00 equiv.) in dry methanol (10 mL) and the mixture stirred under H2 for 1 h.
The reaction mixture was filtered through a pad of Celite®, washed with methanol, and
concentrated. The residue was dissolved in acetonitrile (3 mL) and added dropwise to a
stirred solution of 2-bromoacetophenone (303 mg, 1.52 mmol, 1.00 equiv.) in acetonitrile
(5 mL) at rt. A solution of triethylamine (318 L, 231 mg, 2.28 mmol, 1.50 equiv.) in
acetonitrile (1 mL) was added dropwise over 2 h and the reaction mixture was stirred at rt
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overnight. The mixture was concentrated and then partitioned between CH2Cl2 (25 mL)
and 5% hydrochloric acid (2 x 20 mL). The organic layer was washed with brine (20
mL), dried over MgSO4, filtered, concentrated, and purified by flash chromatography on
silica gel eluting with 5:1 CH2Cl2:EtOAc to give 22 as a yellow solid (303 mg, 64%). Rf
0.63 (3:1 CH2Cl2:EtOAc). []D24 -26.0 (c 1.005, CHCl3) [Lit.24 []D23 -41.8 (c 0.66,
CHCl3)].

1

H NMR (CDCl3, 400 MHz) δ 0.79 (d, J = 6.7 Hz, 3H), 1.02 (d, J = 6.7 Hz,

3H), 1.31 (d, J = 7.4 Hz, 3H), 1.45 (s, 9H), 2.15-2.23 (m, 1H), 3.14-3.22 (m, 1H), 3.93 (d,
J = 5.3 Hz, 1H), 4.61 (dd, J = 9.0, 4.0 Hz, 1H), 5.80 (d, J = 9.2 Hz, 1H), 9.82 (s, 1H); 13C
NMR (CDCl3, 100 MHz) δ 15.3, 16.9, 19.7, 28.3, 29.7, 38.4, 59.0, 64.9, 80.3, 156.1,
172.1, 179.1, 202.2. HRMS (ESI-TOF) calcd for C15H24NaN2O5 (M+Na)+: 335.1577,
obsd: 335.1582.
General procedure for the synthesis of amines 23 and 25.24 Trifluoroacetic acid
(2.0 mL) was added dropwise to a solution of Boc-protected amine (22 or 24) (1.00
equiv.) in CH2Cl2 (2.0 mL) at 0 °C and stirring continued at 0 °C for 2 h followed by the
addition of toluene (10 mL) and removal of solvent in vacuo. The resulting residue was
purified by flash chromatography on silica gel with the less polar byproducts being
flushed with 2-3 columns lengths of 1:1 CH2Cl2:EtOAc and product being eluted with 9:1
CH2Cl2:MeOH.
Synthesis of (3S)-L-valine-(4S)-methyl-succinimide (23).

Starting from Boc-

protected amine 22 (200 mg, 0.64 mmol), the general procedure gave 23 as a light yellow
foam (121 mg, 89%). Rf 0.50 (6:4:1 CHCl3:MeOH;H2O). HRMS (ESI-TOF) calcd for
C10H16N2O3 (M+H)+: 213.1234, obsd: 213.1238.
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Synthesis

of

(3S)--phenylalanine-L-valine-(4S)-methyl-succinimide

(25).

Starting from Boc-protected amine 24 (183 mg, 0.398 mmol), the general procedure gave
25 as a light pink solid (141 mg, 98%). Rf 0.64 (6:4:1 CHCl3:MeOH;H2O). HRMS (ESITOF) calcd for C19H26N3O4 (M+H)+: 360.1918, obsd: 360.1927.
Synthesis

of

(3S)-N-Boc-3-amino--phenylalanine-L-valine-(4S)-methyl-

succinimide (24).13 (S)-N-Boc-3-amino-3-phenylpropanoic acid (255 mg, 0.96 mmol,
1.20 equiv.) was added to a solution of 23 (170 mg, 0.80 mmol, 1.00 equiv.) in dry DMF
(5.0 mL) at 0 °C. HATU (366 mg, 0.96 mmol, 1.20 equiv.) was added to the solution and
the mixture began stirring under N2. A solution of N,N-diisopropylethylamine (349 L,
259 mg, 2.00 mmol, 2.50 equiv.) in dry DMF (1.5 mL) was added dropwise to the
reaction over 1 h, while maintaining the temperature at 0 °C. The reaction was stirred for
an additional 30 min at 0 °C before allowing the reaction mixture to warm to rt where
stirring was continued for 20 h under N2. The solvent was removed in vacuo and the
mixture was partitioned between EtOAc (20 mL) and water (20 mL). The organic layer
was washed with sat’d aq. NaHCO3 (20 mL) and brine (20 mL), dried over MgSO4,
filtered, concentrated and purified by flash chromatography on silica gel eluting with 3:2
Hex:EtOAc to give 24 as a colorless solid (166 mg, 45%). Rf 0.25 (1:1 Hex:EtOAc).
[]D20 -53.2 (c 1.00, CHCl3). 1H NMR (DMSO-d6, 400 MHz) δ 0.77 (d, J = 6.6 Hz, 3H),
0.85 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 7.3 Hz, 3H), 1.34 (s, 9H), 2.23-2.37 (m, 1H), 2.422.50 (m, 1H), 2.71 (dd, J = 13.9, 9.3 Hz, 1H), 2.84-3.03 (m, 1H), 3.99 (d, J = 5.4 Hz,
1H), 4.71 (dd, J = 7.6, 5.3 Hz, 1H), 4.79-4.95 (m, 1H), 7.12-7.39 (m, 6H), 8.01 (d, J = 8.3
Hz, 1H), 11.37 (br s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 15.0, 17.5, 20.0, 28.6, 28.8,
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43.0, 52.1, 58.3, 63.4, 78.3, 126.6, 127.3, 128.7, 144.0, 155.0, 170.4, 174.2, 180.5, 203.7.
HRMS (ESI-TOF) calcd for C24H34N3O6 (M+H)+: 460.2442, obsd: 460.2428.
Synthesis of moiramide B (4). Sorbic acid (75 mg, 0.67 mmol, 1.20 equiv.),
TBTU (215 mg, 0.67 mmol, 1.20 equiv.) and N,N-diisopropylethylamine (242 L, 180
mg, 1.39 mmol, 2.50 equiv.) were added to a solution of 25 (200 mg, 0.56 mmol, 1.00
equiv.) in dry DMF (2 mL) and the mixture stirred for 20 h under N2. The mixture was
partitioned between EtOAc (10 mL) and water (6 mL). The organic layer was washed
with sat’d aq. NaHCO3 (5 mL), brine (5 mL), dried over MgSO4, filtered, and
concentrated. The resulting residue was purified by flash chromatography on silica gel
eluting with 2% NH4OH in 9:1 EtOAc:MeOH to give 4 as a colorless solid (81 mg,
32%).24 Rf 0.54 (100% EtOAc). []D24 -77.5 (c 1.00, MeOH) [Lit.24 []D25 -96.6 (c 0.28,
MeOH)]. CD (c 1 M, MeOH) max() 213.0 (+9.68), 238.0 (-21.08), 292.0 (+0.69),
320.0 (-1.26). CD spectrum displayed max values in good agreement with the literature
though no concentrations were reported.11, 24 1H NMR (DMSO-d6, 400 MHz) δ 0.74 (d, J
= 6.7 Hz, 3H), 0.79 (d, J = 6.7 Hz, 3H), 1.06 (d, J = 7.4 Hz, 3H), 1.77 (d, J = 6.4 Hz, 3H),
2.19-2.34 (m, 1H), 2.62 (dd, J = 14.1, 5.9 Hz, 1H), 2.76 (dd, J = 14.2, 8.7, 1H), 2.83-2.97
(m, 1H), 3.92 (d, J = 5.4 Hz, 1H), 4.62 (dd, J = 8.0, 5.6 Hz, 1H), 5.14-5.29 (m, 1H), 5.91
(d, J = 15.2, 1H), 6.06 (dq, J = 14.9, 6.8 Hz, 1H), 6.18 (dd, J = 14.9, 11.0 Hz, 1H), 6.94
(dd, J = 14.9, 11.0 Hz, 1H), 7.10-7.37 (m, 5H), 8.11 (d, J = 8.4 Hz, 1H), 8.41 (d, J = 8.4
Hz, 1H), 11.35 (br s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 15.0, 17.7, 18.7, 19.9, 28.6,
39.5, 42.4, 50.3, 58.2, 63.5, 123.3, 126.9, 127.3, 128.6, 128.7, 130.3, 137.2, 139.9, 143.3,
164.9, 170.3, 174.2, 180.5, 203.8. HRMS (ESI-TOF) calcd for C25H32N3O5 (M+H)+:
454.2336, obsd: 454.2347.
75

General procedure for the synthesis of allyl ester linker derivatives (27 and 30).29
Concentrated sulfuric acid (2.00 equiv.) was added to a solution of acid (1.00 equiv.) in
allyl alcohol. The solution was heated at reflux for 6 h. The mixture was cooled to rt,
diluted with Et2O (25 mL), and washed with sat’d aq. NaHCO3 (2 x 20 mL). The
aqueous phase was back-extracted with Et2O (15 mL). The combined organic layers
were washed with brine (10 mL), dried over MgSO4, filtered and concentrated. The
resulting oil was purified by flash chromatography on silica gel eluting with 4:1
Hex:EtOAc.
Synthesis of allyl 16-hydroxyhexadecanoate (27).

According to the general

procedure, concentrated sulfuric acid (391 L, 720 mg, 7.34 mmol), 16hydroxyhexadecanoic acid 26 (1.00 g, 3.67 mmol), and allyl alcohol (35 mL) gave 27 as
a colorless solid (704 mg, 61%). Rf 0.61 (1:1 Hex:EtOAc). 1H NMR (CDCl3, 400 MHz)
δ 1.20-1.35 (m, 22H), 1.53-1.65 (m, 4H), 2.33 (t, J = 7.6 Hz, 2H), 3.64 (t, J = 6.6 Hz,
2H), 4.58 (d, J = 5.7 Hz, 2H), 5.24 (d, J = 10.4 Hz, 1H), 5.32 (d, J = 17.2 Hz, 1H), 5.92
(ddt, J = 17.2, 10.4, 5.7 Hz, 1H);

13

C NMR (CDCl3, 100 MHz) δ 24.9, 25.7, 29.1, 29.2,

29.4, 29.6, 32.8, 34.2, 62.9, 64.9, 118.0, 132.3, 173.5. HRMS (ESI-TOF) calcd for
C19H36NaO3 (M+Na)+: 335.2557, obsd: 335.2559.
Synthesis of allyl 8-hydroxyoctanoate (30). According to the general procedure,
concentrated sulfuric acid (133 L, 245 mg, 2.50 mmol), 8-hydroxyoctanoic acid 29 (200
mg, 1.25 mmol), and allyl alcohol (8 mL) gave 30 as a yellow oil (148 mg, 59%). Rf 0.54
(1:1 Hex:EtOAc). 1H NMR (CDCl3, 400 MHz) δ 1.29-1.38 (m, 7H), 1.55 (p, J = 6.7 Hz,
2H), 1.64 (p, J = 6.9 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 3.61 (t, J = 6.6 Hz, 2H), 4.57 (d, J
= 5.7 Hz, 2H), 5.23 (d, J = 10.4 Hz, 1H), 5.31 (d, J = 17.2 Hz, 1H), 5.92 (ddt, J = 17.2,
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10.4, 5.7 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 24.8, 25.5, 28.9, 29.0, 32.6, 34.2, 62.7,
64.9, 118.1, 132.2, 173.5. HRMS (ESI-TOF) calcd for C11H20NaO3 (M+Na)+: 223.1305,
obsd: 223.1302.
General procedure for the synthesis of iodoalkanoic linker derivatives (28 and
31). Polymer-bound triphenylphosphine (100-200 mesh, polystyrene crosslinked with
2% divinylbenzene: ~3 mmol/g loading; 2.18 equiv.) was suspended in dry CH2Cl2 (10
mL). Iodine (2.18 equiv.) was added in portions until the dark color persisted. The
mixture was stirred at rt under N2 for 15 min. Imidazole (2.48 equiv.) was added and the
reaction stirred for an additional 15 min. A solution of compound 27 or 30 (1.00 equiv.)
in dry CH2Cl2 (5 mL) was added and the mixture was heated at reflux for 30 min. The
mixture was filtered to remove the resin and resin-bound byproducts and the resin was
washed with CH2Cl2 (15 mL). The filtrate was washed with sat’d aq. Na2S2O3 (15 mL)
and water (15 mL). The organic layer was dried over MgSO4, filtered, and concentrated.
Synthesis of allyl 16-iodohexadecanoate (28).

Starting from polymer-bound

triphenylphosphine (2.19 g, 8.36 mmol), iodine (2.12 g, 8.36 mmol), imidazole (647 mg,
9.51 mmol), and allyl ester linker 27 (1.20 g, 3.83 mmol), the general procedure gave 28
as a yellow solid (1.26 g, 78%). Rf 0.74 (2:1 Hex:EtOAc). 1H NMR (CDCl3, 400 MHz)
δ 1.21-1.33 (m, 22H), 1.38 (p, J = 7.0 Hz, 2H), 1.62 (p, J = 7.0 Hz, 2H), 1.81 (p, J = 7.2
Hz, 2H), 2.31 (t, J = 7.5 Hz, 2H), 3.17 (t, J = 7.0 Hz, 2H), 4.56 (d, J = 5.6 Hz, 2H), 5.21
(d, J = 10.6 Hz, 1H), 5.30 (d, J = 17.1 Hz, 1H), 5.91 (ddt, J = 17.1, 10.6, 5.6 Hz, 1H); 13C
NMR (CDCl3, 100 MHz) δ 7.0, 24.9, 28.5, 29.1, 29.2, 29.4, 29.5, 29.6, 29.6, 30.5, 33.6,
34.2, 64.8, 117.9, 132.4, 173.2.
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Synthesis of allyl 8-iodooctanoate (31).

Starting from polymer-bound

triphenylphosphine (394 mg, 1.50 mmol), iodine (382 mg, 1.50 mmol), imidazole (116
mg, 1.71 mmol), and allyl ester linker 30 (138 mg, 0.690 mmol), the general procedure
gave 31 as a yellow oil (178 mg, 83%). Rf 0.48 (1:1 Hex:EtOAc). 1H NMR (CDCl3, 400
MHz) δ 1.22-1.33 (m, 7H), 1.40 (p, J = 6.6 Hz, 2H), 1.64 (p, J = 7.3 Hz, 2H), 1.82 (p, J =
7.2 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 4.58 (d, J = 5.7 Hz, 2H),
5.24 (d, J = 10.4 Hz, 1H), 5.32 (d, J = 17.2 Hz, 1H), 5.92 (ddt, J = 17.2, 10.4, 5.7 Hz,
1H);

13

C NMR (CDCl3, 100 MHz) δ 7.2, 24.8, 28.2, 28.9, 30.3, 33.4, 34.1, 65.0, 118.1,

132.3, 173.3.
General procedure for the synthesis of aminooxazole conjugated to linker
derivatives (32-33). Cesium hydroxide (1.00 equiv.) was added to a solution of 13 (1.00
equiv.) in dry DMF (5 mL). Linker derivative (28 or 31) (1.00 equiv.) in dry THF (2 mL)
was added to the reaction and the mixture was heated at reflux for 24 h. Once cooled to
rt, the mixture was filtered and the precipitate was washed with THF. The solvent was
removed in vacuo and the residue was partitioned between EtOAc (10 mL) and water (10
mL) and the organic layer was dried over MgSO4, filtered, and concentrated.
Synthesis of allyl 16-{4-[(2-amino-N-benzyloxazole-5-carboxamido)methyl]
phenoxy}hexadecanoate (32). Starting from cesium hydroxide (224 mg, 1.33 mmol),
aminooxazole 13 (430 mg, 1.33 mmol), and linker 28 (562 mg, 1.33 mmol), the general
procedure gave a residue that was purified by flash chromatography on silica gel eluting
with 3:1 EtOAc:Hex that gave 32 as a pale yellow solid (166 mg, 20%). Rf 0.18 (3:1
EtOAc:Hex).

1

H NMR (CDCl3, 400 MHz) δ 1.18-1.36 (m, 22H), 1.44 (p, J = 7.2 Hz,

2H), 1.63 (p, J = 6.9 Hz, 2H), 1.75 (p, J = 7.1 Hz, 2H), 2.32 (t, J = 7.5 Hz, 2H), 3.93 (t, J
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= 6.3 Hz, 2H), 4.53-4.68 (m, 6H), 5.22 (d, J = 10.4 Hz, 1H), 5.30 (d, J = 17.2 Hz, 1H),
5.91 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 6.00 (br s, 2H), 6.85 (d, J = 7.9 Hz, 2H), 7.02-7.38
(m, 8H);

13

C NMR (CDCl3, 100 MHz) δ 25.0, 26.1, 29.1, 29.3, 29.5, 29.6, 29.7, 34.3,

49.1, 50.2, 64.9, 68.1, 114.8, 118.1, 127.6, 127.8, 128.5, 128.9, 132.3, 133.3, 138.1,
158.7, 159.5, 162.0, 173.6. HRMS (ESI-TOF) calcd for C37H52N3O5 (M+H)+: 618.3901,
obsd: 618.3883.
Synthesis

of

allyl

phenoxy}octanoate (33).

8-{4-[(2-amino-N-benzyloxazole-5-carboxamido)methyl]

Starting from cesium hydroxide (257 mg, 1.53 mmol),

aminooxazole 13 (494 mg, 1.53 mmol), and linker 31 (474 mg, 1.53 mmol), the general
procedure gave a residue that was purified by flash chromatography on silica gel eluting
with 4:1 EtOAc:Hex that gave 33 as a yellow oil (160 mg, 21%).

Rf 0.43 (2.5:1

EtOAc:Hex). 1H NMR (CDCl3, 400 MHz) δ 1.25-1.52 (m, 7H), 1.65 (p, J = 6.8 Hz, 2H),
1.77 (p, J = 6.9 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 3.93 (t, J = 6.3 Hz, 2H), 4.48-4.69 (m,
6H), 5.22 (d, J = 10.4 Hz, 1H), 5.31 (d, J = 17.1 Hz, 1H), 5.90 (ddt, J = 17.1, 10.4, 5.4
Hz, 1H), 6.00 (br s, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.96-7.41 (m, 8H); 13C NMR (CDCl3,
100 MHz) δ 24.9, 25.9, 29.0, 29.1, 29.2, 34.2, 49.2, 65.0, 68.0, 114.8, 118.2, 127.6,
128.9, 132.3, 133.3, 138.4, 158.7, 159.5, 161.7, 173.5. HRMS (ESI-TOF) calcd for
C29H36N3O5 (M+H)+: 506.2649, obsd: 506.2656.
General procedure for the synthesis of allyl deprotected aminooxazole-linker
derivatives (34-35). A 2M aqueous NaOH solution (5 mL) was added to a solution of
aminooxazole-linker derivative (32-33) (1.00 equiv.) in methanol (5 mL) and THF (2
mL) and the mixture was stirred at rt for 18 h. Concentrated hydrochloric acid was added
dropwise to the reaction mixture until it became acidic by pH paper (pH ~3-4). The
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aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organic layers
were washed with brine (6 mL), dried over MgSO4, filtered, and concentrated.
Synthesis of 16-{4-[(2-amino-N-benzyloxazole-5-carboxamido)methyl]phenoxy}
hexadecanoic acid (34). Compound 32 (89 mg, 0.144 mmol) gave 34 as a yellow solid
(74 mg, 89%) and was taken into the next step without further purification. Rf 0.42 (4:1
EtOAc:Hex).

HRMS (ESI-TOF) calcd for C34H48N3O5 (M+H)+: 578.3588, obsd:

578.3573.
Synthesis of 8-{4-[(2-amino-N-benzyloxazole-5-carboxamido)methyl]phenoxy}
octanoic acid (35). Compound 33 (160 mg, 0.317 mmol) gave 35 as a yellow oil (104
mg, 71%) and was taken into the next step without further purification. Rf 0.23 (4:1
EtOAc:Hex).

HRMS (ESI-TOF) calcd for C26H32N3O5 (M+H)+: 466.2336, obsd:

466.2324.
Synthesis of dual-ligand inhibitor with 15C-linker (5). Compound 34 (69 mg,
0.120 mmol, 1.00 equiv.), HOBt (48 mg, 0.359 mmol, 3.00 equiv.), EDC (35 mg, 0.179
mmol, 1.50 equiv.), and triethylamine (50 L, 36 mg, 0.359 mmol, 3.00 equiv.) were
added to a solution of 25 (109 mg, 0.303 mmol, 2.50 equiv.) in dry DMF (3 mL) and the
mixture stirred for 20 h under N2. The mixture was partitioned between EtOAc (15 mL)
and water (10 mL). The organic layer was washed with sat’d aq. NaHCO3 (10 mL), brine
(10 mL), dried over MgSO4, filtered, concentrated, and purified by flash chromatography
on silica gel eluting with 2:1 EtOAc:Hex  4:1 EtOAc:Hex to give 5 as a yellow solid
(21 mg, 19%). Rf 0.70 (92:8 CH2Cl2:MeOH). []D24 -28.5 (c 0.425, MeOH). 1H NMR
(CD3OD, 400 MHz) δ 0.79 (d, J = 6.7 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H), 1.16 (d, J = 7.3
Hz, 3H), 1.20-1.41 (m, 22H), 1.42-1.52 (m, 2H), 1.53-1.65 (m, 2H), 1.70-1.82 (m, 2H),
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2.11-2.29 (m, 2H), 2.32-2.47 (m, 1H), 2.63-2.93 (m, 3H), 3.06-3.20 (m, 1H), 3.95 (t, J =
5.9 Hz, 2H), 4.63 (s, 2H), 4.68 (s, 2H), 4.76 (d, J = 4.5 Hz, 1H), 5.28-5.43 (m, 1H), 6.806.91 (m, 2H), 7.05-7.40 (m, 13H). HRMS (ESI-TOF) calcd for C53H71N6O8 (M+H)+:
919.5328, obsd: 919.5344.
Synthesis of dual-ligand inhibitor with 7C-linker (6). Compound 35 (104 mg,
0.224 mmol, 1.20 equiv.) was added to a solution of 25 (67 mg, 0.186 mmol, 1.00 equiv.)
in dry DMF (3.0 mL) at 0 °C. HATU (85 mg, 0.224 mmol, 1.20 equiv.) was added to the
solution and the mixture began stirring under N2.

A solution of N,N-

diisopropylethylamine (97 L, 72 mg, 0.559 mmol, 3.00 equiv.) in dry DMF (1.0 mL)
was added dropwise to the reaction over 1 h at 0 °C. The reaction was stirred for an
additional 30 min at 0 °C before allowing reaction to warm to rt where stirring was
continued for 20 h under N2. The solvent was removed in vacuo and the mixture was
partitioned between EtOAc (10 mL) and water (10 mL). The organic layer was washed
with sat’d aq. NaHCO3 (10 mL) and brine (10 mL), dried over MgSO4, filtered,
concentrated, and purified by flash chromatography on silica gel eluting with 4:1
EtOAc:Hex  100% EtOAc to give 6 as a yellow oil (26 mg, 17%). Rf 0.59 (92:8
CH2Cl2:MeOH). []D24 -22.1 (c 1.17, MeOH). 1H NMR (CD3OD, 500 MHz) δ 0.74 (d,
J = 6.7 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H), 1.11 (d, J = 7.4 Hz, 3H), 1.21-1.36 (m, 7H),
1.37-1.47 (m, 2H), 1.48-1.60 (m, 2H), 1.62-1.77 (m, 2H), 2.08-2.24 (m, 2H), 2.30-2.41
(m, 1H), 2.71-2.84 (m, 2H), 3.02-3.15 (m, 1H), 3.29 (s, 1H), 3.78-3.97 (m, 2H), 4.57 (s,
2H), 4.63 (s, 2H), 4.72 (d, J = 4.8 Hz, 1H), 5.24-5.39 (m, 1H), 6.83 (d, J = 7.4 Hz, 2H),
7.04-7.40 (m, 13H). HRMS (ESI-TOF) calcd for C45H55N6O8 (M+H)+: 807.4076, obsd:
807.4077.
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2.4.2 Kinetic Assays
Acetyl-CoA carboxylase was purified according to Broussard et al. from a strain
of E. coli that overexpresses the four genes that encode the enzyme.20 The activity of
acetyl-CoA carboxylase was determined spectrophotometrically by measuring the
production of ADP using pyruvate kinase and lactate dehydrogenase and following the
oxidation of NADH at 340 nm. Each reaction mixture contained 17.5 units of lactate
dehydrogenase, 10.5 units of pyruvate kinase, 0.5 mM phosphoenolpyruvate, 0.2 mM
NADH, 20 mM MgCl2, 15 mM potassium bicarbonate, and 100 mM HEPES (pH 8.0).
For reactions measuring the effects of inhibition versus ATP, each reaction contained a
concentration of 0.2 mM acetyl-CoA, with ATP concentrations ranging from 0.8 M to
56 M.

For reactions measuring the effects of inhibition versus acetyl-CoA, each

reaction contained a concentration of 5 M ATP, with acetyl-CoA concentrations ranging
from 50 M to 1000 M. All reactions were conducted in a total of 0.5 mL in a 1 cm
pathlength quartz cuvette and all reactions were initiated by the addition of enzyme.
Spectrophotometric data were collected using an Agilent Cary 60 UV-Vis
spectrophotometer interfaced with a personal computer with a data acquisition program.
2.4.3 Kinetic Analysis
Data were analyzed by nonlinear regression using the computer programs of
Cleland.41 Data describing competitive inhibition were fitted to Eq. 1, where v is the
initial velocity, V is the maximal velocity, Km is the Michaelis constant, I is the
concentration of the inhibitor, and Kis is the slope inhibition constant.
Eq. 1
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Data describing noncompetitive inhibition were fitted to Eq. 2, where v is the
initial velocity, V is the maximal velocity, Km is the Michaelis constant, I is the
concentration of the inhibitor, and Kis and Kii are the slope and intercept inhibition
constants, respectively.
Eq. 2

2.4.4 Determination of MICs
Determination of MICs was conducted by Dr. Gregory Robertson at UT
Southwestern Medical Center (Dallas, TX) in accordance with the Clinical and
Laboratory Standards Institute (CLSI) methodology using the broth microdilution
methods with cation-adjusted Mueller Hinton (MHII) medium.42 The strains tested were
used with permission from the strain collection of TenNor Therapeutics. Test organisms
were streaked onto agar medium and incubated overnight at 35 °C.

Experimental

compounds were tested over a concentration range prepared by two-fold serial dilution
after solubilizing compounds in 100% DMSO (or sterile water for gentamicin and
kanamycin) to achieve a final stock concentration of 10 mg/L. A standardized inoculum
of 5 x 105 CFU/mL in a volume of 0.1 mL was incubated with antibiotic for 18-24 h at 35
°C. The MIC was scored visually as the lowest concentration of antibiotic where no
growth is apparent by visual inspection for turbidity.
2.4.5 Sensitization Assay using PMBN
A culture of E. coli strain JM109 was grown overnight in Luria broth (LB) at 37
°C. Culture tubes containing 2 mL of fresh LB media were inoculated with 10 L of the
saturated E. coli culture. Polymyxin B nonapeptide (PMBN) was dissolved in water to
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achieve a 1 mM stock and inoculated into the tubes to generate final concentrations of
0.5, 1, 5, and 10 g/mL. Dual-ligand 5 was dissolved in 100% DMSO to achieve a 5 mM
stock solution and inoculated into the tubes to generate final concentrations of 1, 10, 50,
and 100 M. After inoculation, the culture tubes were incubated for 4 hours at 37 °C.
Optical density (OD) readings were measured at 600 nm in 1 mL plastic cuvettes.
Spectrophotometric data were collected using an Agilent Cary 60 UV-Vis
spectrophotometer.
2.4.6 Generation of Spontaneous Resistant Mutant Strains and Resistance Studies
Single-step spontaneous resistance selections were undertaken by Dr. Gregory
Robertson at UT Southwestern Medical Center on agar medium using overnight saturated
cultures grown in cation-adjusted Mueller Hinton (MHII). Briefly, compounds were
added to molten MHII agar after allowing time to cool to 55 °C. Compounds were dosed
in two-fold increasing concentrations starting at 1x MIC. The test organism was grown
overnight to saturation in MHII broth. The cells were concentrated by centrifugation and
the viable number of CFU plated was determined by serial dilution and plating. Each
drug plate received a total of 4 x 109 CFU/plate (i.e., 0.1 mL plated of 4 x 1010 CFU/mL
in the concentrated culture). Plates were monitored for the appearance of drug-resistant
colonies. For selection of spontaneous moiramide-resistance in the wild-type S. aureus
and E. coli tolC backgrounds, moiramide was dosed at ~2x to 8x their respective MICs
and potential drug-resistant isolates were evaluated after secondary passage through a
drug-free intermediate. Stable moiramide-resistance was verified by broth microdilution
MIC assays, as above. The mutant prevention concentration (MPC) was defined as the
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lowest consecutive drug concentration capable of fully suppressing the emergence of
antibiotic-resistant bacterial subpopulations.43
2.5
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CHAPTER 3: MECHANISM OF ACTION FOR THE ANTIBACTERIAL
AGENT MOIRAMIDE B
3.1

INTRODUCTION
As the frequency of antibiotic resistant bacteria steadily increases, there is an urgent

need for new antibacterial agents. Fatty acid synthesis is required for membrane biogenesis
in bacteria, so the enzymes in this pathway are targets for antibacterial development.1
Acetyl-CoA carboxylase (ACC) catalyzes the committed and regulated step in fatty acid
synthesis.2 The bacterial form of the enzyme consists of three proteins: biotin carboxylase,
biotin carboxyl carrier protein, and carboxyltransferase,3 which catalyze the following twostep reaction.

Scheme 3.1. The two half-reactions catalyzed by acetyl-CoA carboxylase.
Biotin carboxylase (BC) catalyzes the first half-reaction in Scheme 3.1, which
involves the ATP-dependent phosphorylation of bicarbonate to form a reactive
carboxyphosphate intermediate.4 The carboxyl group is then transferred to the vitamin
biotin, which in vivo, is covalently attached to the biotin carboxyl carrier protein (BCCP).
The second half-reaction is catalyzed by the carboxyltransferase (CT) component, which
transfers the carboxyl group from carboxybiotin to acetyl-CoA to make malonyl-CoA.
Biotin carboxylase and carboxyltransferase can be purified and retain their activity when
free biotin is used as a substrate instead of BCCP.1
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Both the biotin carboxylase and the carboxyltransferase components of acetyl-CoA
carboxylase can serve as targets for antibacterial agents. Biotin carboxylase is the target
for three different types of antibacterial compounds: pyridopyrimidines5, aminooxazoles6
and benzimidazole-carboxamides7.

In contrast, there is currently only one class of

molecules known to inhibit carboxyltransferase, the natural products moiramide B and
andrimid. Moiramide B is a pseudopeptide pyrrolidinedione that was isolated from the
marine bacterium Pseudomonas fluorescens and was determined to be a potent broadspectrum antibiotic.8

Ten years after the discovery of the antibacterial potential of

moiramide B, Freiberg et al. determined that carboxyltransferase was the target.9 The
inhibition of carboxyltransferase by moiramide B was competitive with respect to malonylCoA (Ki = 5 nM) and noncompetitive with respect to biocytin.1,10
The structure of moiramide B is composed of four distinct domains: 1) an
unsaturated fatty acid chain, 2) the -amino acid -phenylalanine, 3) an L-valine derived
-ketoamide group, and 4) a pyrrolidinedione head group (Figure 3.1).

Figure 3.1. Structure of moiramide B with four domains: 1) unsaturated fatty acid chain,
2) -amino acid -phenylalanine, 3) L-valine derived -ketoamide, and 4) pyrrolidinedione
head group.
The assembly of moiramide B is likely genetically similar to the biosynthesis of
andrimid, which utilizes a cluster of 21 genes encoding a hybrid polyketide synthase/non-

1

The activity of carboxyltransferase is measured in the reverse or non-physiological
direction where malonyl-CoA and biocytin (a biotin analog) are the substrates. The
formation of the product acetyl-CoA is detected using the coupling enzymes, citrate
synthase and malate dehydrogenase.
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ribosomal peptide synthetase.11 The biosynthesis starts with the tail (domain 1) and
proceeds to the head (domain 4), whereas synthetic procedures for moiramide B start with
the head (domain 4) and conclude with the tail (domain 1).12-13 Given the significant
resources that a bacterium must commit to produce each of the domains of moiramide B,
why have these particular molecular structures survived natural selection? In other words,
how do each of the domains of moiramide B contribute to its overall potent antibacterial
activity? The objective of this study is to dissect moiramide B into molecular fragments
and determine the function of those fragments with respect to the inhibition of
carboxyltransferase and the antibacterial properties.
3.2

RESULTS AND DISCUSSION

3.2.1 Three-dimensional Structure of Moiramide B Bound to Carboxyltransferase
The first approach for determining the function of each of the molecular fragments
was to determine the structure of moiramide B bound to carboxyltransferase. Synthetic
procedures outlining the production of moiramide B in milligram quantities for
crystallization trials have recently been described (Chapter 2). Carboxyltransferase from
E. coli10 was cocrystallized with the synthetically produced moiramide B (Figure 3.2), Xray diffraction data were collected at the Advanced Photon Source and the structure was
solved by molecular replacement. The data collection and refinement statistics are shown
in Figure 3.3.

Figure 3.2. Crystal of moiramide B bound to carboxyltransferase. The crystallization
conditions were: 0.1 M MES (pH 6.5), 0.1 M malonate, and 20% w/v polyacrylic acid
2100. The space group was P6522.
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Data Collection
Wavelength (Å)
Resolution (Å)
Temperature (K)
Space group
Cell dimensions
a (Å)
c (Å)
Number of CT subunits per
asymmetric unit
Unique reflections
Rpim a,b (%)
Completeness (%)
Redundancies
I /σ (I )
Refinement Statistics
Resolution range (Å)
Number of reflections
σ cutoff used in refinement
Rwork /Rfreec (%)
Number of refined atoms
Protein
Heterogen atoms
Water
Average B-factors (Å2 )
Protein
Water
Zn2+
Inhibitor
R.m.s. deviations
Bond lengths (Å)
Bond angles (°)
Ramachandran plot (%)
Favored
Disallowed

0.97918
3.53
100
P 65 22
156.170
193.158
1
17 327
5.8 (54.9)
98.5 (99.0)
7.2 (7.4)
11.1 (1.5)
135 - 3.53
16 439
none
21.00/25.93
4445
34
2
133.7
68.3
171.0
156.7
0.011
1.82
79.55
6.87

a

Values in parentheses are for the highest-resolution shell.
Rpim is a redundancy-independent measure of the quality of intensity measurements.
Rpim = ∑hkl (1/(n -1))1/2 ∑i |Ihkl,i - <Ihkl>| / ∑hkl ∑i Ihkl,i, where Ihkl,I is the scaled intensity of the ith measurement
of reflection, h, k, l, <Ihkl> is the average intensity for that reflection, and n is the redundancy.
c
R = ∑ ||Fo| - |Fc|| / ∑ |Fo|, where Fo and Fc are the observed and calculated structure factors amplitudes. Rfree
is calculated using 5.1% of reflections omitted from the refinement.
b

Figure 3.3. Data Collection and Refinement Statistics.
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The electron density for the moiramide B ligand is shown in Figure 3.4. While the
resolution is 3.5 Å, density was clearly observed for the pyrrolidinedione head group
(domain 4). The electron density extends down the backbone of the -ketoamide group
(domain 3) as well as into the -phenylalanine moiety (domain 2), indicating binding
interactions are taking place with these portions of the natural product. However, the
resolution is not sufficient to pinpoint the structural features required for binding. No
density was observed for the unsaturated fatty acid chain (domain 1) indicating it is very
flexible when bound to the enzyme.

Figure 3.4. Structure of moiramide B in the active site of E. coli carboxyltransferase.
The Fo-Fc electron density map is contoured at 2.5σ. Hydrogen bonds are indicated by
dashes.
Carboxyltransferase is a heterotetramer with two active sites that lie at the interface
between the and subunits.14

A space-filling model of a heterodimer of

carboxyltransferase with moiramide B bound in the active site is shown in Figure 3.5. A
closer view of moiramide B bound in the active site shows that the major interactions are
with the carbonyl oxygens of the pyrrolidinedione moiety (Figure 3.6). One carbonyl
group forms two hydrogen bonds with residues from the subunit (Gly206 and Ser205),
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while the other carbonyl group forms two hydrogen bonds with residues from the
subunit (Gly205 and Ala165). This contradicts an earlier report that andrimid, and by
inference moiramide B, interact solely with the subunit of carboxyltransferase.11

Figure 3.5. Space-filling model of moiramide B bound to carboxyltransferase. The
subunit of carboxyltransferase is in gold while the subunit is in purple. Moiramide
B is represented in gray sticks.

Figure 3.6. Close-up view of the interactions of the pyrrolidinedione moiety of moiramide
B with the active site residues of carboxyltransferase.
In carboxyltransferase, oxyanion holes are needed to stabilize the enolates that
form in each substrate during catalysis. As shown in Figure 3.7, (A), the peptidic groups
from adjacent glycine residues (Gly206 and Gly207 in the -subunit and Gly204 and
Gly205 in the -subunit) form the oxyanion holes that stabilize the enolate and imidate
anions in acetyl-CoA and biotin, respectively.14 One residue from each subunit that is used
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to form the oxyanion hole hydrogen bonds to each pyrrolidinedione carbonyl (Gly206 in
the subunit and Gly205 in thesubunit), Figure 3.7, (B).

Figure 3.7. (A) The oxyanion holes in the and subunits of carboxyltransferase that
stabilize the enolate of acetyl-CoA in the -subunit and the imidate of biotin in the subunit. (B) The pyrrolidinedione carbonyls interact with oxyanion hole residues, Gly205
from the -subunit and Gly206 from the -subunit.
The structure of moiramide B bound to carboxyltransferase shows how nature took
advantage of the structural and mechanistic features (i.e. the oxyanion holes) of the enzyme
to create a molecule that inhibits activity and is also bactericidal. The structure also
explains why nature incorporated a pyrrolidinedione instead of 1,3-cyclopentanedione into
moiramide B; delocalization of the electrons from the nitrogen atom into the adjacent
carbonyls makes the oxygen atoms have more oxyanion-like character. Furthermore,
Pohlmann et al. synthesized six-membered piperidinedione derivatives of moiramide B
which did not exhibit any antibacterial activity.13 Therefore, if 2,6-piperidinedione was
used in place of pyrrolidinedione, the carbonyls would not have the appropriate geometry
to interact with the oxyanion holes. In fact, Pohlmann et al. found that as more bulky and
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hydrophobic groups were attached to the pyrrolidinedione nitrogen atom, there was a
progressive decrease in both IC50 and MIC values13 indicating that the size of this moiety
was critical for enzyme inhibition and, thus, antibacterial activity. The structure-activity
relationship (SAR) studies of Pohlmann et al. also indicated that the (4S)-methyl group on
the pyrrolidinedione moiety was very important for antibacterial activity. The removal of
the methyl group or replacement with an ethyl group resulted in a total loss of activity. 13,
15

Therefore, it is tempting to speculate that the methyl group also contributes to the

oxyanion character of the carbonyl oxygen via an inductive effect.
The lack of electron density for the tail (domain 1) of moiramide B bound to
carboxyltransferase indicates that it is very flexible and, therefore, unlikely to have any
significant interactions with carboxyltransferase. This result is consistent with the findings
of Pohlmann et al. who found that a wide range of functional groups were tolerated at the
tail (domain 1) of moiramide B with respect to the inhibition of carboxyltransferase and
the antibacterial activity of the derivatives.13 This leads to the assumption that the
unsaturated nature of the tail end is strictly a necessary component for entry into the
bacterial cell.
The structure of moiramide B bound to carboxyltransferase also provides insight
into a naturally occurring resistance mutation. The bacterium (Pantoea agglomerans) that
produces the moiramide B analog, andrimid, is resistant to the effects of the molecule
because of a mutation in the subunit (M203L in E. coli carboxyltransferase).16 A study
by Liu et al. revealed the M203L mutation in E. coli made the bacteria more resistant to
andrimid.16 The Met203 residue is very close to one of the residues in the subunit
(Gly205) that interacts with one of the carbonyl oxygens of the pyrrolidinedione; therefore,
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the M203L mutation could cause a local conformational change that decreases or
eliminates the binding of andrimid (and by inference moiramide B) to the enzyme. Another
intriguing possible mechanism for how the M203L mutation leads to resistance against
andrimid is the -phenylalanine moiety of moiramide B is within 5 Å from the sulfur atom
of Met203 (Figure 3.8). A report by Valley et al. suggested that the sulfur of a methionine
side chain can form a stable interaction with aromatic residues within ~5 Å.17 Thus, the
incorporation of the unnatural -amino acid of phenylalanine into andrimid and moiramide
B may be to allow this strong interaction with the enzyme to occur and contributing to the
nanomolar affinity of the ligand for the enzyme.

Figure 3.8. The -phenylalanine moiety of moiramide B shown within 5 Å of the
methionine sulfur atom of the Met203 side chain on the -subunit of carboxyltransferase.
3.2.2

Structure-Activity Relationships of Moiramide B
Since the moiramide B used in the structural studies was synthetic in origin, this

afforded the ability to distinguish the structural characteristics of the molecule required for
enzyme inhibition versus the structural features needed for antibacterial activity. The
structural fragments of moiramide B tested for enzyme inhibition and antibacterial activity
are shown in Figure 3.9. Since the synthesis of moiramide B progresses in a head-to-tail
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fashion, the starting pyrrolidinedione fragment came in the form of the commercially
available product, succinimide (compound 1). Compounds 2-4 were intermediates in the
synthesis of moiramide B (compound 5), while compound 6, the tail fragment, was
synthesized for this analysis.

Figure 3.9. Structures of moiramide B intermediates: succinimide (1), (4S)-methyl-2,5pyrrolidinedione (2), (3S)-L-valine-(4S)-methyl-2,5-pyrrolidinedione (3), (3S)-phenylalanine-L-valine-(4S)-methyl-2,5-pyrrolidinedione (4), as well as moiramide B (5)
and the tail fragment (6).
The initial velocity of carboxyltransferase was measured in the presence of 50 nM
of each of the compounds, while the substrates malonyl-CoA and biocytin were held
constant at a subsaturating level. The results are shown in Figure 3.10, (A). Succinimide
(compound 1) was, within error, not an inhibitor of carboxyltransferase. However, addition
of the (4S)-methyl substituent to succinimide (compound 2) resulted in a dramatic decrease
in carboxyltransferase activity. The inhibition of carboxyltransferase was stronger with
the attachment of the L-valine group. Another significant decrease in activity occurred
with the addition of the -phenylalanine moiety (compound 4), which corroborates the
potential interaction between the aromatic group of the phenylalanine and the methionine
sulfur atom to increase the binding affinity of moiramide B. Moiramide B (compound 5)
showed a similar level of activity to compound 4 indicating the addition of the fatty acyl
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tail has no further impact on inhibition. The tail end alone (compound 6) of moiramide
exhibited no inhibition of carboxyltransferase.
The absence of any inhibitory activity for the tail end (compound 6) of moiramide
B (compound 5) is consistent with the hypothesis that the (4S)-methyl pyrrolidinedione
group is required for inhibiting carboxyltransferase, while the fatty acyl tail must only be
needed for gaining entry into the bacterial cell. To test this hypothesis, the enzyme
inhibition data for each of the compounds in Figure 3.10, (A) was compared to their
antibacterial activity. A final concentration of 50 M for each compound was added to
culture media inoculated with E. coli and incubated for 4 hrs. As shown in Figure 3.10,
(B), all of the compounds, except for moiramide B (compound 5), did not exhibit any
antibacterial activity.

Figure 3.10. (A) Inhibitory activity of compounds 1-6. Initial velocities of
carboxyltransferase were measured in the presence of 50 nM of each compound while
holding the substrates (malonyl-CoA and biocytin) at subsaturating levels. (B)
Antibacterial activity of compounds 1-6. Final concentrations of 50 M for each
compound were inoculated with E. coli and incubated at 37 °C. After a 4 hour incubation,
the absorbance at 600 nm was measured.
Even though compounds 2, 3, and 4 all inhibited carboxyltransferase significantly,
they did not exhibit any antibacterial activity at a concentration of 50 M. The only
difference between compound 4 and moiramide B (compound 5) is the absence of the fatty
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acyl tail. Therefore, the role of the fatty acyl tail in the mechanism of action of moiramide
B appears to be transport of the molecule into the bacterial cell.
3.3

CONCLUSIONS
These studies reveal how nature expropriated the oxyanion holes in

carboxyltransferase to design a molecule that is not only a potent enzyme inhibitor, but
also a potent antibacterial agent. In nature’s version of structure-based drug design, a
methyl pyrrolidinedione functionality evolved to inhibit carboxyltransferase by binding in
the oxyanion holes found in both the  and subunits. Subsequent additions of L-valine
and -phenylalanine increased the affinity of the molecule for carboxyltransferase,
however, none of these additions produced a molecule with strong antibacterial activity.
As a result, nature attached an unsaturated fatty acyl tail to the molecule that allowed it to
enter the bacterium.
The results described in this report also provide intriguing scaffolds from which to
build new antibacterial agents against a novel target molecule, acetyl-CoA carboxylase.
For instance, structure-activity studies on the methyl group of pyrrolidinedione can be done
to increase the affinity for carboxyltransferase and improve the potency of moiramide B.
Lastly, it will be interesting to see if these scaffolds can also be used in the design of
inhibitors of human acetyl-CoA carboxylase II, which has a similar mechanism to the
bacterial enzyme (i.e. it also utilizes two oxyanion holes for catalysis). The mitochondrial
isoform (or acetyl-CoA carboxylase II) is involved in regulating fatty acid oxidation and is
a target for anti-obesity agents.18
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3.4

EXPERIMENTAL SECTION

3.4.1 Materials and Methods
All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, Acros,
NovaBiochem, and Fluka and used without further purification. Diisopropylethylamine
and triethylamine were dried and distilled from CaH2 and stored over KOH pellets. Dry
methanol was distilled from Mg turnings and stored over 3Å molecular sieves. All
reactions were performed under a dry nitrogen atmosphere unless otherwise noted. Flash
chromatography was performed using 230-400 mesh silica gel (40-63 m) from Fluka.
Thin layer chromatography was performed on aluminum-backed 60 F254 silica plates from
EMD Chemicals, Inc.
polarimeter.

1

H and
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Optical rotations were recorded on a Jasco P-2000 digital
C NMR spectra were collected at room temperature on a Bruker

AV-400 spectrometer. All NMR experiments were performed in deuterated solvents and
the chemical shifts are reported in standard δ notation as parts per million, using
tetramethylsilane (TMS) and CDCl3 as an internal standard with coupling constants (J)
reported in Hertz (Hz). High resolution mass spectrometry (HRMS) was carried out using
an Agilent 6210 electrospray ionization-time-of-flight (ESI-TOF) mass spectrometer.
Synthesis of (4S)-methyl-pyrrolidine-2,5-dione (2). A catalytic amount of 5% Pd/C
(100 mg, 20% w/w) was added to a solution of (4S)-methyl-N-O-benzyl-pyrrolidine-2,5dione (500 mg, 2.28 mmol, 1.00 equiv.) in dry methanol (25 mL) and the mixture stirred
under H2 for 1 h. The reaction mixture was filtered through a pad of Celite®, washed with
methanol, and concentrated. The residue was dissolved in acetonitrile (5 mL) and added
dropwise to a stirred solution of 2-bromoacetophenone (454 mg, 2.28 mmol, 1.00 equiv.)
in acetonitrile (5 mL) at rt. A solution of triethylamine (477 L, 346 mg, 3.42 mmol, 1.50
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equiv.) in acetonitrile (2 mL) was added dropwise over 2 h and the reaction mixture was
stirred at rt overnight. The mixture was concentrated and then partitioned between CH2Cl2
(20 mL) and 5% hydrochloric acid (2 x 20 mL). The organic layer was washed with brine
(20 mL), dried over MgSO4, filtered, concentrated, and purified by flash chromatography
on silica gel eluting with 5:1 CH2Cl2:EtOAc to give 2 as a clear oil (25 mg, 10%). Rf 0.56
(4:1 EtOAc:CH2Cl2). []D20 -16.3 (c 0.13, MeOH). 1H NMR (CDCl3, 400 MHz) δ 1.37
(d, J = 7.2 Hz, 3H), 2.39 (dd, J = 16.1, 2.9 Hz, 1H), 2.81-3.07 (m, 2H), 8.22 (s, 1H); 13C
NMR (CDCl3, 100 MHz) δ 16.5, 36.2, 37.6, 176.4, 180.7. HRMS (ESI-TOF) calcd for
C5H8NO2 (M+H)+: 114.0550, obsd: 114.0548.
Synthesis of (2E,4E)-N-[(S)-1-phenylbutyl]hexa-2,4-dienamide (6). Sorbic acid
(50 mg, 0.45 mmol, 1.20 equiv.) was added to a solution of (S)-1-phenylbutylamine (55
mg, 0.37 mmol, 1.00 equiv.) and TBTU (155 mg, 0.48 mmol, 1.30 equiv.) in DMF (5 mL)
followed by addition of N,N-diisopropylethylamine (162 µL, 120 mg, 0.93 mmol, 2.50
equiv.) and the mixture was stirred under N2 for 20 h. The solvent was removed in vacuo
and the resulting residue was purified by flash chromatography on silica gel eluting with
1:1 Hex:EtOAc to give 6 as a light yellow solid (66 mg, 73%). Rf 0.56 (1:1 Hex:EtOAc).
[]D24 -136.2 (c 1.00, CHCl3). 1H NMR (CDCl3, 400 MHz) δ 0.90 (t, J = 7.3 Hz, 3H),
1.18-1.42 (m, 2H), 1.70-1.87 (m, 5H), 5.05 (q, J = 7.7 Hz, 1H), 5.79 (d, J = 15.0 Hz, 1H),
5.95-6.23 (m, 3H), 7.10-7.38 (m, 6H);

13

C NMR (CDCl3, 100 MHz) δ 14.5, 17.9, 19.5,

38.4, 52.5, 122.5, 125.9, 127.5, 127.7, 129.3, 130.5, 136.8, 140.6, 142.7, 165.7. HRMS
(ESI-TOF) calcd for C16H22NO (M+H)+: 244.1696, obsd: 244.1704.
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3.4.2

Enzyme Purification
Carboxyltransferase from E. coli was purified as previously described.10 Briefly,

the genes coding for the - and -subunits of carboxyltransferase were placed in a
minioperon on the plasmid pET14b such that the N-terminus of the -subunit contained a
His-tag. The genes were overexpressed and the protein was purified using nickel affinity
chromatography followed by gel-filtration chromatography.
3.4.3 Crystallization and Data Collection
Crystals were obtained by sitting drop vapor diffusion at 22 °C using a solution of
10 mg/mL carboxyltransferase and 300 M moiramide B. The crystallization condition
contained a reservoir solution of 0.1 M MES (pH 6.5), 0.1 M malonate, and 20% w/v
polyacrylic acid 2100. The sitting drop contained a well to protein ratio of 2:2 L. Crystals
appeared after 1-2 weeks and were cryoprotected with a 20% v/v ethylene glycol/reservoir
solution and then mixing that solution with crystal mother liquor in a 1:1 ratio. The crystal
was submerged in the cryoprotectant and then immediately flash-cooled in liquid nitrogen.
X-ray diffraction data were collected to 3.53 Å at the Advanced Photon Source beamline
NE-CAT 24-ID-E equipped with the ADSC Q315r detector. The data was processed and
scaled using XDS.19 Data collection and refinement statistics are in Figure 3.3.
3.4.4 Crystal Structure Determination
The crystal structure was solved by Dr. Svetlana Pakhomova (LSU) by molecular
replacement. The molecular replacement procedure was applied to locate a solution using
the program MOLREP.20 A carboxyltransferase subunit of ACC from E. coli (PDB
accession code 2F9Y) was used as a search model. The positioned MR model was refined
against 3.52 Å using the “jelly” body and the maximum likelihood refinement in
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REFMAC.21 A difference Fourier map unambiguously revealed the presence of the
inhibitor between the alpha and beta chains (Figure 3.4). The final model consists of
residues 1-319 for the alpha chain, residues 23-287 for the beta chain, one Zn2+ cation, one
inhibitor molecule and two water molecules. The program Coot20 was used for model
building throughout the refinement.
3.4.5 Kinetic Assays
Carboxyltransferase activity was measured in the reverse, non-physiological
direction and was determined spectrophotometrically by measuring the production of
acetyl-CoA using citrate synthase and malate dehydrogenase and following the reduction
of NAD+ at 340 nm.

Each reaction mixture contained 0.12 mg/mL of malate

dehydrogenase, 0.05 mg/mL of citrate synthase, 0.5 mM NAD+, 0.01 mM malic acid, 0.6
mg/mL bovine serum albumin (BSA), and 100 mM Tris (pH 8.0). All reactions held the
substrates malonyl-CoA and biocytin (a biotin analog) constant at 150 M and 6 mM,
respectively. A final concentration of 50 nM of compounds 1-6 was added to measure the
effect on activity. All reactions were conducted in a total of 0.5 mL in a 1 cm pathlength
quartz cuvette and all reactions were initiated by the addition of enzyme and were
measured in triplicate. Spectrophotometric data were collected using an Agilent Cary 60
UV-Vis spectrophotometer interfaced with a personal computer with a data acquisition
program.
3.4.6 Whole-cell Growth Assays
A culture of E. coli strain JM109 was grown overnight in Luria broth (LB) at 37
°C. Culture tubes containing 2 mL of fresh LB media were inoculated with 10 L of the
saturated E. coli culture. Compounds 1-6 were dissolved in 100% DMSO to achieve a 5
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mM stock solution and inoculated into tubes to generate final concentrations of 50 M.
After inoculation, the culture tubes were incubated for 4 hours at 37 °C. Optical density
(OD) readings were measured at 600 nm in 1 mL plastic cuvettes. Spectrophotometric
data were collected using an Agilent Cary 60 UV-Vis spectrophotometer.
3.5
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CHAPTER 4: CONCLUSIONS AND OUTLOOK
4.1

SUMMARY
The overall goal of this research was the development of dual-ligand inhibitors

against the novel target acetyl-CoA carboxylase that could act as antibacterial agents. The
identification of antibacterial agents for both enzymes of the acetyl-CoA carboxylase
(ACC) reaction, biotin carboxylase (BC) and carboxyltransferase (CT), allowed for the
covalent attachment of these inhibitors via saturated hydrocarbon linkers (15 carbons and
7 carbons) into multitarget agents. Although a multitarget approach will not solve the
resistance problem permanently, it can delay the onset of resistance that is being observed
with single agent antibiotics. For example, spontaneous resistance mutations of single
targets occur between 10-6 and 10-9; therefore, a multitarget approach should result in a
much lower frequency of resistance because bacteria would have to develop viable
resistance mutations on more than one target.1
Once the dual-ligand inhibitors were generated, the inhibitory and antibacterial
properties were determined. Enzyme kinetic studies on acetyl-CoA carboxylase yielded
an unexpected result. The aminooxazole inhibitor exhibits competitive inhibition against
the isolated BC subunit, but for the studies with the ACC complex, it displayed a
noncompetitive inhibition pattern. Due to the high intracellular concentration of ATP,
ACC is likely saturated with ATP in vivo. Therefore, the noncompetitive inhibition pattern
indicates the aminooxazole compound can still inhibit BC even in the presence of
saturating levels of ATP. These results show that it is crucial that any potential antibacterial
agents targeting the BC subunit of ACC must be characterized with the ACC complex and
not just the isolated subunit in order to determine how BC inhibitors will act in vivo.
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The antibacterial properties of the parent compounds and the dual-ligands were
tested against a variety of both Gram-negative and Gram-positive bacteria. The 15-carbon
dual-ligand did not display any antibacterial activity to any of the tested strains, while the
7-carbon dual-ligand exhibited activity against not only membrane-compromised E. coli,
but also several Gram-positive strains. The frequency of resistance studies using the 7carbon dual-ligand showed a restriction for the selection of resistance with a frequency of
<2.5 x 10-10, which was a much lower frequency than expected with single agents. Studies
inoculating the 15-carbon dual-ligand with the antibiotic polymyxin B nonapeptide
revealed the longer linker was impeding the ability for this dual-ligand to diffuse across
the bacterial membrane. The dual-ligand studies provide a proof-of-concept for the use of
multitargeted therapies against bacterial ACC, and also revealed the selection of the linking
component between multiple agents is of vital importance for inhibitory and antibacterial
activity.
Since the moiramide B used for the dual-ligand studies was synthesized, this
allowed for the determination of the structural features of moiramide B that contribute to
its mechanism of action. Previous studies have shown the (4S)-methyl group on the
pyrrolidinedione moiety was very important for antibacterial activity, but the exact
mechanism was never determined.2-3 The elucidation of our three-dimensional structure
shows the five-membered ring geometry of the pyrrolidinedione allows the carbonyls to
bind directly in the oxyanion holes of carboxyltransferase. The incorporation of the central
nitrogen atom instead of a carbon atom also was strategic to increase binding affinity by
causing delocalization of electrons to make the carbonyls have more ‘oxyanion-like’
character. Essentially, nature designed moiramide B to explicitly take advantage of the
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mechanistic features of carboxyltransferase by binding in the oxyanion holes that are
needed for catalysis. Furthermore, the enzymatic assays confirmed the unsaturated fatty
acyl tail has no impact on the inhibitory activity, and additional whole-cell growth studies
led us to conclude the unsaturated tail was strictly implemented to allow for moiramide B
to enter the bacterium.
4.2

FUTURE DIRECTIONS
The ACC dual-ligand inhibitors have created new avenues for exploring

multiligand therapeutics against this novel target. The incorporation of a more potent, and
ideally, broad-spectrum BC inhibitor, in conjugation with moiramide B, could lead to more
potent dual-ligand inhibitors for bacterial ACC. An additional design modification to the
dual-ligand design would be implementing various linking components. Based on our
results, altering the length, and possibly other physiochemical properties (e.g.,
hydrophobicity, degree of unsaturation), can effect both the inhibitory and antibacterial
activities of dual-ligand inhibitors. The information gained during these dual-ligand
studies cannot only be utilized in the generation of new dual-ligand inhibitors for ACC, but
also can be applied towards multiligand inhibitors against other known enzyme complexes.
The three-dimensional structure of moiramide B bound to carboxyltransferase
provided valuable information on the essential binding features. A structure with a higher
resolution could more accurately pinpoint the position of the pseudopeptide moieties on
the moiramide B backbone. The orientation of these domains in relation to the side chain
residues of the CT subunits would provide more insight into how to design inhibitors that
would interact with these residues to increase the potency of moiramide B or moiramide B
analogs.
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A particularly interesting residue is the Met203 residue found on the subunit of
CT. The bacterium that produces a moiramide B analog (andrimid) is resistant to this
compound due to the mutation of the methionine to a leucine, indicating the leucine causes
a disruption in binding affinity. The sulfur atom of the Met203 residue (E. coli numbering)
is within 5 Å from the unnatural -amino acid of phenylalanine found in moiramide B. A
report by Valley et al. suggests the interaction between the methionine sulfur atom and an
aromatic residue can form a stable interaction.4

Mutagenic analysis of Met203 and

subsequent measurement of the inhibitory activity would assist in the confirmation of this
residue being involved with the recognition and binding of moiramide B. Mutagenesis
studies, as well as obtaining a crystal structure that diffracts to a higher resolution, could
greatly benefit the development of novel antibiotics that can target the carboxyltransferase
enzyme of ACC.
The precedent set by the dual-ligand inhibitor studies in this dissertation provide a
strong foundation for the development of subsequent multitarget agents against bacterial
acetyl-CoA carboxylase and other antibacterial targets.

The structural studies of

moiramide B provide a framework from which to design new antibacterial agents against
the CT component of ACC as well as lay the groundwork for potential virtual screening
studies to identify potent inhibitors of carboxyltransferase.
4.3
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